

FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 0380-P02714USO
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/980650
INTERNATIONAL APPLICATION NO. PCT/GB00/01633	INTERNATIONAL FILING DATE 27 April 2000	PRIORITY DATE CLAIMED 28 April 1999	
TITLE OF INVENTION PESTICIDAL FUSIONS			
APPLICANT(S) FOR DO/EO/US CHRISTOU, Paul; MEHLO, Luke			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.			
4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).			
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).			
b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.			
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).			
6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).			
a. <input type="checkbox"/> is attached hereto.			
b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).			
7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).			
b. <input type="checkbox"/> have been communicated by the International Bureau.			
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired			
d. <input type="checkbox"/> have not been made and will not be made.			
8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).			
9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11 to 20 below concern document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.			
14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
15. <input type="checkbox"/> A substitute specification.			
16. <input type="checkbox"/> A change of power of attorney and/or address letter.			
17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1 821 - 1.825.			
18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).			
19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).			
20. <input checked="" type="checkbox"/> Other items or information: Copy of Form PCT/IB/308 (1996) Abstract of the Disclosure (1 Page)			

U.S. APPLICATION NO. 09/980650 INTERNATIONAL APPLICATION NO. PCT/GB00/01633	ATTORNEY'S DOCKET NUMBER 0380-P02714USO
--	--

21 <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =	CALCULATIONS PTO USE ONLY <table style="width: 100%;"> <tr> <td style="width: 50%;">\$ 890.00</td> <td style="width: 50%;"></td> </tr> <tr> <td>\$ 130.00</td> <td></td> </tr> </table>	\$ 890.00		\$ 130.00	
\$ 890.00					
\$ 130.00					

Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	130.00
---	--	--	--	----	--------

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	- 20 =		x \$18.00	\$	468.00
Independent claims	- 3 =		x \$84.00	\$	-0-
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$	-0-
TOTAL OF ABOVE CALCULATIONS =				\$	1,488.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	-0-
SUBTOTAL =				\$	1,488.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	-0-
TOTAL NATIONAL FEE =				\$	1,488.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	-0-
TOTAL FEES ENCLOSED =				\$	1,488.00
				Amount to be refunded:	\$
				charged:	\$

a. ☒ A check in the amount of \$ 1,488.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to Deposit Account No. 04-1406. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
 information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

HAGAN, Patrick J.
 Dann Dorfman Herrell & Skillman
 1601 Market Street, Suite 720
 Philadelphia, Pennsylvania 19103-2307
 United States of America


 SIGNATURE
 PATRICK J. HAGAN

 NAME
 27,643

 REGISTRATION NUMBER

Rec'd PCT/PTO 05 APR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6/B

In re the Application of)
Paul Christou et al.)
Serial No. 09/980,650)
Filed: October 26, 2001)
For: "Pesticidal Fusions")

SUBMISSION OF SEQUENCE LISTING
UNDER 37 C.F.R. §§1.821-1.825 AND SECOND PRELIMINARY AMENDMENT

Please amend the specification as follows:

(Page 31, Line 1) Site directed mutagenesis of ricin toxin B chain gene. Four mutagenic oligonucleotides were used in PCR reactions to create an EcoRI and a HindIII restriction site at selected positions along the ricin toxin B chain gene in the plasmid pWT (Wales et.al., 1991) - these are shown in Fig 1A. The five mutagenic oligonucleotides (mutated bases underlined) were:

LF1=5' CAACAACAAAGGAATTCATGCTGATG 3' (SEQ ID NO: 12)

LB1=5' GGACACACACACTGCAAGCTTGTAATC 3' (SEQ ID NO: 13)

LB2=5' CGGATCCGAAAGCTTCACATCTAACAC 3' (SEQ ID NO: 14)

LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3' (SEQ ID NO: 15)

(Page 43, Line 34) Total RNA was extracted from 100 mg leaf tissue of transformed and wild type rice plants using the RNeasy Plant Mini kit (Qiagen) according to the supplier's recommendations. RT-PCRs were carried out using the Access-PCR kit (Promega) according to the manufacturer's instructions. We used 100 ng total RNA and 50 pmol of each primer. Primers CRF1 and CRR1 amplify both *cry1ab* and *cry1Ac*, while primers RTF1 and RTR1 amplify the RTB gene fragment. The primer sequences were as follows: CRF1 (5'-CGCATTGAAAC CGTTTACACTC

CCA-3'; SEQ ID NO:16), CRR1 (5'-CTTGGGCAGAACCCACGGAAGCTACC-3';
SEQ ID NO: 17), RTF1 (5'-GATGTTTGTATGGATCCTCAGCCCA-3'; SEQ ID
NO: 18) and RTR1 (5'GCCGAACAATGGTTGTAA CAAAAGG-3'; SEQ ID NO:
19).

Please amend the Claims as Follows:

Claim 41 (Amended) An oligonucleotide selected from the
group consisting of:

LF1=5' CAACAACAAAGGAAATTCATGCTGATG 3' (SEQ ID NO: 12),
LB1=5' GGACACACACACTGCAAGCTTGTAATC 3' (SEQ ID NO: 13),
LB2=5' CGGATCCGAAGCTTCACATCTAACAC 3' (SEQ ID NO: 14), or
LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3' (SEQ ID NO: 15).

A marked-up copy of the specification and claim
amendments are provided in Appendix A.

REMARKS

The present submission is in response to the Official
communication dated February 5, 2002 enclosing a Notification
Of Missing Requirements Under 35 U.S.C. §371 In The United
States Designated/Elected Office in connection with the above-
identified patent application.

To comply with the requirements under 37 C.F.R. §1.821-
1.825, submitted herewith is a sequence listing of the
nucleotide sequences presented in the above-referenced
application. The sequence listing is being submitted in both
paper copy and computer-readable form. Applicants
respectfully request entry of the sequence listing into the
above-identified patent application. The undersigned hereby
verifies that the paper copy and computer readable form of the
sequence listing are identical and do not contain any new
matter.

In addition, the specification and Claim 41 have been
amended herewith to include the sequence identifiers (SEQ ID
NO'S) for the sequences appearing in the text of the above-

identified application.

In the event that a fee is required, the Commissioner is authorized to charge the account of the undersigned, Account No. 04-1406. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By Patrick J. Hagan
Patrick J. Hagan
PTO Registration No. 27,643

Telephone: (215) 563-4100

Enclosure: Appendix A

Appendix A

(Page 31, Line 1) Site directed mutagenesis of ricin toxin B chain gene. Four mutagenic oligonucleotides were used in PCR reactions to create an EcoRI and a HindIII restriction site at selected positions along the ricin toxin B chain gene in the plasmid pWT (Wales et.al., 1991) - these are shown in Fig 1A. The five mutagenic oligonucleotides (mutated bases underlined) were:

LF1=5' CAACAACAAAGGAATTCATGCTGATG 3' (SEO ID NO: 12)
 LB1=5' GGACACACACACTGCAAGCTTGTAATC 3' (SEO ID NO: 13)
 LB2=5' CGGATCCGAAAGCTTCACATCTAACAC 3' (SEO ID NO: 14)
 LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3' (SEO ID NO: 15)

(Page 43, Line 34) Total RNA was extracted from 100 mg leaf tissue of transformed and wild type rice plants using the RNeasy Plant Mini kit (Qiagen) according to the supplier's recommendations. RT-PCRs were carried out using the Access-PCR kit (Promega) according to the manufacturer's instructions. We used 100 ng total RNA and 50 pmol of each primer. Primers CRF1 and CRR1 amplify both *cry1Ab* and *cry1Ac*, while primers RTF1 and RTR1 amplify the *RTB* gene fragment. The primer sequences were as follows: CRF1 (5'-CGCATTGAAAC CGGTTACACTC CCA-3'; SEO ID NO:16), CRR1 (5'-CTTGGGCAGAACCCGGAAGCTACC-3'; SEO ID NO: 17), RTF1 (5'-GATGTTTGTATGGATCCTCAGCCCA-3'; SEO ID NO: 18) and RTR1 (5'GCCGAACAATGGTTGTAA CAAAGG-3'; SEO ID NO: 19).

Claim 41 (Amended) An oligonucleotide selected from the group consisting of:

LF1=5' CAACAACAAAGGAATTCATGCTGATG 3' (SEO ID NO: 12),
 LB1=5' GGACACACACACTGCAAGCTTGTAATC 3' (SEO ID NO: 13),
 LB2=5' CGGATCCGAAAGCTTCACATCTAACAC 3' (SEO ID NO: 14), or
 LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3' (SEO ID NO: 15).

09/980650

THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC10 Rec'd PCT/PTO

26 OCT 2001

United States Serial No. : Not Yet Assigned
International Application No. : PCT/GB00/01633
International Filing Date : 27 April 2000
Inventor(s) : Paul Christou et al.
Title : PESTICIDAL FUSIONS

#3/A

Suite 720
1601 Market Street
Philadelphia, PA 19103
(215) 563-4100 (telephone)
(215) 563-4044 (facsimile)
Our File No. 0380-P02714US0

Assistant Commissioner
for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Dear Sir:

Before calculation of the filing fee, please amend the above-referenced patent application as follows:

In the Specification:

After the claims, please insert the attached Abstract of the Disclosure.

In the Claims:

Please amend the claims as follows:

4 (Amended) A nucleic acid as claimed in claim 1 wherein the binding domain binds carbohydrate.

6 (Amended) A nucleic acid as claimed in claim 4 wherein the binding domain is derived from a lectin.

9 (Amended) A nucleic acid as claimed in claim 2 which comprises all or part of Seq ID No 1 (CryIA(b)) or Seq ID No 2 (CryIA(c)) or a sequence degeneratively equivalent thereto.

10 (Amended) A nucleic acid as claimed in claim 2 which comprises all or part of Seq ID No 3 (RTB1), Seq ID No 4 (RTB2) or Seq ID No 5 (RTB3) or a sequence degeneratively equivalent thereto.

11 (Amended) A nucleic acid as claimed in claim 9 which comprises the CryIA-RTB combination shown in any one of Seq ID No 6 (CryIA(b)-RTB1); Seq ID No 7 (CryIA(b)-RTB2); Seq ID No 8 (CryIA(b)-RTB3); Seq ID No 9 (CryIA(c)-RTB1); Seq ID No 10 (CryIA(c)-RTB2); or Seq ID No 11 (CryIA(c)-RTB3) or a sequence degeneratively equivalent thereto.

12 (Amended) A nucleic acid as claimed in claim 2 which comprises a nucleotide sequence which is a homologous variant of any of Seq ID Nos 1 to 11.

13 (Amended) A method of producing the nucleic acid of claim 1, which method comprises the step of combining nucleic acid encoding a toxin with a nucleic acid encoding heterologous binding domain, wherein said binding domain is capable of binding non-specifically to a cell membrane without disrupting it.

14 (Amended) A method as claimed in claim 13 wherein the method further comprises the step of modifying the sequence of the toxin or binding domain by way of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid.

16 (Amended) A recombinant vector comprising a nucleic acid as claimed in claim 1.

17 (Amended) A vector as claimed in claim 16 wherein the nucleic acid of claim 1 is operably linked to a promoter.

19 (Amended) A vector as claimed in claim 16 which is a baculovirus vector or a vector suitable for use in a plant.

20 (Amended) A method for transforming a host cell which method

includes the step of introducing a vector of claim 16 into the cell and causing or allowing recombination between the vector and the cell genome to introduce the nucleic acid into the genome.

21 (Amended) A host cell containing the nucleic acid of claim 1.

22 (Amended) A host cell transformed with the nucleic acid of claim 1.

23 (Amended) A host cell as claimed in claim 21 which is a plant cell.

26 (Amended) A process for producing a transgenic plant, which process comprises the steps of:

- (a) transforming a host cell by introducing a recombinant vector comprising a nucleic acid as claimed in claim 1 into the cell and causing or allowing recombination between the vector and the cell genome to introduce the nucleic acid into the genome, thereby to produce a transformed plant cell; and
- (b) regenerating a plant from said transformed host cell.

27 (Amended) A plant obtainable by the process of claim 26, which comprises a host cell containing a nucleic acid molecule encoding a pesticidal fusion polypeptide comprising (i) a toxin domain; and (ii) a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting said membrane, said host cell being a plant cell.

28 (Amended) A plant which is a clone, selfed or hybrid progeny, or other descendant of the plant of claim 27.

29 (Amended) A plant as claimed in claim 27 which is a monocot.

31 (Amended) A part or propagule of the plant of claim 27.

32 (Amended) A method of influencing or affecting the toxicity

of a plant to a pest, which method includes the step of causing or allowing expression from a nucleic acid of claim 1 in the plant.

33 (Amended) A pesticidal fusion polypeptide encoded by the nucleic acid of claim 1.

34 (Amended) A method for producing the polypeptide of claim 33 which method comprises the step of causing expression from a nucleic acid molecule, encoding a pesticidal fusion polypeptide comprising (i) a toxin domain and (ii) a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting said membrane, in a suitable host cell.

37 (Amended) A method for controlling pests comprising treating said pests with the polypeptide of claim 33.

39 (Amended) A method as claimed in claim 37 wherein the pest is a species of insect.

Add new claims 42-49 as follows:

42 A nucleic acid as claimed in claim 10 which comprises the CryIA-RTB combination shown in any one of Seq ID No 6 (CryIA(b)-RTB1); Seq ID No 7 (CryIA(b)-RTB2); Seq ID No 8 (CryIA(b)-RTB3); Seq ID No 9 (CryIA(c)-RTB1); Seq ID No 10 (CryIA(c)-RTB2); or Seq ID No 11 (CryIA(c)-RTB3) or a sequence degeneratively equivalent thereto.

43 A host cell containing the vector of claim 16.

44 A host cell transformed with the vector of claim 16.

45 A host cell as claimed in claim 22 which is a plant cell.

46 A host cell as claimed in claim 45 wherein the plant is a monocot plant.

47 A host cell as claimed in claim 46 wherein the monocot is maize or rice.

48 A method as claimed in claim 38 wherein the pest is a species of insect.

49 A method as claimed in claim 48 wherein the species is selected from *Lepidoptera*, *Coleoptera*, *Culicidae*, *Simuliidae*, *Hymenoptera*, *Homoptera*, *Orthoptera* and *Diptera*.


REMARKS

The purpose of this Preliminary Amendment is to delete multiple claims dependencies and to add claims directed to preferred embodiments of the invention.

A marked-up version of the present claim amendments is attached hereto.

The foregoing amendments do not introduce new matter into the present application and, therefore, should not be deemed objectionable. Entry of the present amendments is respectfully requested.

Dated: October 26, 2001


Patrick J. Hagan
Registration No. 27,643
Attorney for Applicants

MARKED-UP VERSION OF THE AMENDED CLAIMS

4 (Amended) A nucleic acid as claimed in claim 1 [any one of the preceding claims] wherein the binding domain binds carbohydrate.

6 (Amended) A nucleic acid as claimed in claim 4 [or claim 5] wherein the binding domain is derived from a lectin.

9 (Amended) A nucleic acid as claimed in claim 2 [any one of claims 2 to 8] which comprises all or part of Seq ID No 1 (CryIA(b)) or Seq ID No 2 (CryIA(c)) or a sequence degeneratively equivalent thereto.

10 (Amended) A nucleic acid as claimed in claim 2 [any one of claims 2 to 9] which comprises all or part of Seq ID No 3 (RTB1), Seq ID No 4 (RTB2) or Seq ID No 5 (RTB3) or a sequence degeneratively equivalent thereto.

11 (Amended) A nucleic acid as claimed in claim[s] 9 [or claim 10] which comprises the CryIA-RTB combination shown in any one of Seq ID No 6 (CryIA(b)-RTB1); Seq ID No 7 (CryIA(b)-RTB2); Seq ID No 8 (CryIA(b)-RTB3); Seq ID No 9 (CryIA(c)-RTB1); Seq ID No 10 (CryIA(c)-RTB2); or Seq ID No 11 (CryIA(c)-RTB3) or a sequence degeneratively equivalent thereto.

12 (Amended) A nucleic acid as claimed in claim 2 [any one of claims 2 to 8] which comprises a nucleotide sequence which is a homologous variant of any of Seq ID Nos 1 to 11.

13 (Amended) A method of producing the nucleic acid of claim 1 [any one of claims 1 to 12], which method comprises the step of combining nucleic acid encoding a toxin with a nucleic acid encoding heterologous binding domain, wherein said binding domain is capable of binding non-specifically to a cell membrane without disrupting it.

14 (Amended) A method as claimed in claim 13 wherein the

method further comprises the step of modifying the sequence of the toxin or binding domain [be] by way of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid.

16 (Amended) A recombinant vector comprising a nucleic acid as claimed in claim 1 [any one of claims 1 to 12].

17 (Amended) A vector as claimed in claim 16 wherein the nucleic acid of claim 1 [any one of claims 1 to 12] is operably linked to a promoter.

19 (Amended) A vector as claimed in claim 16 [any one of claims 16 to 18] which is a baculovirus vector or a vector suitable for use in a plant.

20 (Amended) A method for transforming a host cell which method includes the step of introducing a vector of claim 16 [any one of claims 16 to 19] into the cell and causing or allowing recombination between the vector and the cell genome to introduce the nucleic acid into the genome.

21 (Amended) A host cell containing the nucleic acid of claim 1 [any one of claims 1 to 12 or the vector of any one of claims 16 to 19].

22 (Amended) A host cell transformed with the nucleic acid of claim 1 [any one of claims 1 to 12 or the vector of any one of claims 16 to 19].

23 (Amended) A host cell as claimed in claim 21 [or claim 22] which is a plant cell.

26 (Amended) A process for producing a transgenic plant, which process comprises the steps of:

(a) [performing the method of claim 20] transforming a host cell by introducing a recombinant vector comprising a nucleic acid as claimed in claim 1 into the cell and causing or allowing recombination between the vector and the cell genome

to introduce the nucleic acid into the genome, thereby to produce a transformed plant cell; and

(b) regenerating a plant from said transformed host cell.

27 (Amended) A plant obtainable by the process of claim 26, which comprises [the] a host cell containing a nucleic acid molecule encoding a pesticidal fusion polypeptide comprising (i) a toxin domain; and (ii) a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting said membrane, said host cell being a plant cell [of any one of claims 23 to 25].

28 (Amended) A plant which is a clone, selfed or hybrid progeny, or other descendant of the plant of claim 27[, and which comprises the host cell of any one of claims 23 to 25].

29 (Amended) A plant as claimed in claim 27 [or claim 28] which is a monocot.

31 (Amended) A part or propagule of the plant of claim 27 [any one of claims 27 to 30 which comprises the host cell of any one of claims 23 to 25].

32 (Amended) A method of influencing or affecting the toxicity of a plant to a pest, which method includes the step of causing or allowing expression from a nucleic acid of claim 1 [any one of claims 1 to 12] in the plant.

33 (Amended) A pesticidal fusion polypeptide encoded by the nucleic acid of claim 1 [any one of claims 1 to 12].

34 (Amended) A method for producing the polypeptide of claim 33 which method comprises the step of causing expression from a nucleic acid [of any one of claims 1 to 12] molecule, encoding a pesticidal fusion polypeptide comprising (i) a toxin domain and (ii) a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting said membrane, in a suitable host cell.

37 (Amended) A method for controlling pests comprising treating said pests with [the use of] the polypeptide of claim 33.

39 (Amended) A method as claimed in claim 37 [or claim 38] wherein the pest is a species of insect.

ABSTRACT

Disclosed are polynucleotides encoding a pesticidal fusion polypeptide comprising (i) a toxin domain; and (ii) a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting that membrane. Preferably the toxin domain is derived from a *Bacillus thuringiensis* cry toxin (e.g. CryIA (b) or (c)) and the binding domain is derived from a lectin (e.g. ricin toxin B chain). The use of such fusions may help to inhibit the acquisition of resistance in a pest population treated with the polypeptide. A further aspect of the invention is a method of assessing the toxicity of a polypeptide to a pest species by expressing a nucleic acid encoding said polypeptide in a host cell from that species, observing the viability of the cell and correlating the results of the observation with the toxicity of the polypeptide, wherein the viability is determined by assessing esterase activity or membrane.

PESTICIDAL FUSIONSTECHNICAL FIELD

5 The present invention relates to novel pesticidal fusion polypeptides having binding and toxic portions. It further relates to methods and materials for generating and employing such polypeptides, and also assays and kits for assaying the toxicity of polypeptides.

10 PRIOR ART

Toxins derived from *Bacillus thuringiensis* (Bt) are well known in the art to have insecticidal properties. In nature, large protoxin molecules (130-160 kDa) are solubilised in the alkaline environment of the insect midgut. The solubilised 15 toxins are then proteolytically cleaved to smaller fragments (30-80 kDa). Following solubilisation and activation of delta endotoxin crystals, the toxin interacts with specific surface receptors of midgut cells and forms pores in the membrane. The ionic balance of the cells is disrupted and the 20 cells lyse.

Of particular interest to users of Bt toxins are their host range, toxicity at low concentration, and the capacity of 25 targeted insects to evolve resistance.

A variety of experiments have been reported which investigate these various issues, with a view to improving one or more of them with respect to the native toxin.

30

Thus it is generally accepted that presence of specific receptors on the apical membrane plays an important role in the specificity of Bt toxins (1). Under such circumstances, toxin potency may depend on receptor abundance and its 35 affinity for the protein and also on the ability of the toxin to form pores. Insecticidal crystal proteins CryIA(a) and CryIA(c) are 82% homologous yet the latter protein has a 10-fold higher insecticidal activity towards *Heliothis virescens*

and *Trichoplusia ni* than CryIA(a) (4). Homolog-scanning and reciprocal recombinations between these two genes indicated that amino acids 335-450 on CryIA(c) are associated with the activity against *T. ni* whereas amino acids 335-615 on the same toxin are required to exchange full *H. virescens* specificity (4).

In general, the specificity of an insecticidal protein is the result of several functions, including proteolytic processing by the insect midgut proteases, receptor binding and/or cytolytic functions (4). Results of terminal deletions of a lepidopteran specific insecticidal crystal protein indicated that deletions to the 10th codon from the 5' end or the 645th codon from the 3' end did not abolish toxicity (5).

Through site directed mutagenesis, Cry toxins have been tentatively determined to have three functional domains. Domain I is involved in toxin insertion into the membrane and affects ion channel function, domain II is involved in receptor binding and insertion into the membrane, and domain III is involved in ion channel function, receptor binding and insertion into the membrane (6).

Binding studies have been performed with two Bt delta endotoxins (Bt2, a 130 kDa recombinant crystalline protein from *B. thuringiensis* subsp. *berliner*) and Bt4412 (a 136 kDa crystalline protein from *B. thuringiensis* subsp. *thuringiensis*) on brush boarder membrane vesicles of the tobacco hornworm (*Manduca sexta*) and the cabbage butterfly (*Pieris brassicae*) (12). The Bt2 active protein (60kDa) binds to and kills insects of both species whereas the Bt4412 active protein is highly toxic only to *M. sexta* larvae (12). It was revealed in this study that *P. brassicae* has two distinct binding sites for Bt2 and Bt4412 toxins because the two proteins competed negligibly for each others binding site

(12).

A receptor for the CryIA(b) toxin was cloned from the midgut epithelial cells of the susceptible tobacco hornworm, *M. sexta* (13). The receptor, a 210 kDa membrane glycoprotein was determined to have 30-60% similarity and 20-40% identity to the caderin superfamily of proteins (13). Caderins are membrane glycoproteins and believed to mediate calcium-dependant cell aggregation and sorting (13). The proper function of the receptor was not elucidated. Suggestions though were that it may be involved in membrane transport, a function similar to that of the caderin-like human intestinal peptide transport protein, which channels peptide antibiotics through epithelial cells lining the small intestine (13). *B. thuringiensis* toxins are thought to act primarily at epithelial cells in the midgut of sensitive insects (13).

Another binding protein was purified from *M. sexta* and shown to be 120 kDa in size (14). The same protein, aminopeptidase N, was purified from *Lymantra dyspar* (the gypsy moth) brush boarder membrane vesicles (14). When tested against, CryIA(a), CryIA(b), CryIIA, CryIC, CryIIIA, CryIIB, CryID, CryIF, and CryIVD, aminopeptidase N purified from *L. dyspar* showed negligible binding activity (14). In contrast, aminopeptidase N purified from *M. sexta* was shown to bind CryIA(a), CryIA(b), and CryIA(c) with strong affinity (14). This disparity in the binding activity of aminopeptidase N, is unresolved. Instead it was speculated that either the protein differs according to the insect from which it was purified or that the differences reflect variations in the sensitivities of protocols employed (14). One crop pest, the diamondback moth (*Plutella xylostella*) has evolved resistance to Bt in open field populations, though laboratory selection experiments showed that many insects can develop resistance to Bt genes (17). It was shown that an autosomal recessive

gene in *P. xylostella* confers extremely high resistance to four Bt toxins CryIA(a), CryIA(b), CryIA(c) and CryIF (16). This suggest that such a mutation conferring resistance to the four Bt toxins results in the disruption of binding to a single insect protein which acts as a receptor for all the four Bt toxins (16, 18). This suggests that resistance to even multiple-Bt containing plants is a real possibility.

WO 91/17254 (The regents of the university of California) discloses a method for improving the host range or toxicity of insecticidal toxins. Essentially the insecticidal protein were combined with the specific gut-epithelium-binding glycoprotein gp64 derived from the *Autographa californica* multiple nuclear polyhedrosis virus (MNPV). This glycoprotein was said to interact with epithelial cell surface receptors, allowing concentration on, and entry into, midgut cells. In an alternative embodiment it was suggested that the Cyt A protein could be used to enhance toxicity. This protein was said to bind fatty acids in the lipid portion of cells, disrupting them through a detergent-like mode of action. The implications for resistance, if any, are not discussed.

The binding domains in natural Bt genes have also been swapped with other Bt genes to alter the toxicity of the proteins (see e.g. De Maagd et al (1996) Appl Env Microb 62 No 5:1537-1543). As described above, e.g. with reference to (16), this strategy may not give improved properties as regards possible resistance.

In the light of these observations it can be seen that novel toxin pesticidal materials, particularly those which offer an alternative approach or some advantage over those described above, would provide a contribution to the art.

DISCLOSURE OF THE INVENTION

The present inventors have synthesised fusion protein genes which express highly toxic fusion proteins. These proteins comprise a toxin domain fused to a heterologous binding domain which enhances the efficacy of the toxin portion. The binding domain is preferably one which can bind non-specifically to cell membranes without disrupting them - thereby allowing concentration and immobilisation of the toxin domain at its site of action without the requirement for particular receptors to be present. This has been exemplified using a Bt-derived portion and a carbohydrate binding portion, such as the galactose binding domain of the ricin toxin B chain gene.

The toxicity of the expression product has been demonstrated to be superior to be either of the constituent parts of the fusion protein, using a novel modified assay employing an insect cell-line and a pair of fluorescent dyes. The *in vitro* bioassay for the assessment of toxicity of the fusion gene products was developed and is based on the Ethidium homodimer 1 and Calcein AM. The two phlorophores have previously been used mainly in live/dead toxicity assays (39). These and other aspects of the invention will be described hereinafter.

Thus in a first aspect of the present invention there is disclosed a nucleic acid molecule encoding a pesticidal fusion polypeptide comprising

- (i) a toxin domain
- (ii) a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting that membrane.

By 'pesticidal' is meant having toxicity against any one or more types of pest, particularly economically significant invertebrate pests including insects and other arthropods e.g. arachnida. Insects include all developmental stages of insect. Particular classes of insect of interest include Lepidoptera, Coleoptera, Culicidae, Simuliidae, Hymenoptera,

Homoptera, Orthoptera and Diptera.

By 'fusion polypeptide' is meant a polypeptide comprising two or more components which are heterologous to each other i.e. not part of a naturally occurring single polypeptide chain. Optionally a linker region may be included which may facilitate the folding of the domains into their natural conformation by reducing steric hindrance between the domains.

By 'toxin' is meant a material which is toxic to pests, preferably at a quantity capable of being ingested by a pest. The toxin portion of the fusion protein may be synthetic or from a natural source e.g. prokaryotes, eukaryotes (including fungi, plants and animals). Particularly envisaged is use of proven protein toxins (such as the Bt toxins, or plant defensive allochemics e.g. protease inhibitors such as that from cowpea or soybean) or portions thereof. Preferably these will be pesticidal but be non-toxic to humans and animals. The toxin will preferably be one which has its actual site of action at the cell membrane.

The Bt toxins discussed above are particularly effective as sources of the toxin component. In the most preferred forms of the first aspect of the invention, the toxin is derived from a Bt cry polypeptide. Thus in one embodiment of this aspect the toxin is Bt cryIA(b) or (c).

The 'binding' domain of the fusion polypeptide can bind non-specifically to a cell membrane without disrupting it, and is thus non-toxic *per se*.

'Non-specifically' in this context means not requiring a particular, specific, receptor. This has the advantage that it reduces the probability that the pest will be able to develop resistance to the fusion through a mutation in the nucleic acid sequence encoding a toxin receptor, as is

thought to be the case with some Bt resistance (see refs 16,17,18). It provides an alternative approach to physical methods which may be used to minimise the likelihood of resistance developing i.e. mixing Bt-transformed plants with
5 non-transformed plants during sowing to minimise selective pressure.

The 'binding' domain is non-toxic *per se* i.e. although it may enhance the toxicity of the toxin domain, it does not itself
10 cause significant, or more preferably any, disruption to the cell membrane either when used alone in the fusion protein. Thus the binding portion effectively serves to allow the toxin to exert its effect, but preferably does not alter the mode of action of the toxin mechanism, thereby providing a
15 more predictable specificity and response. This is particularly useful in embodiments wherein the fusion protein may enter the animal food chain, and where the toxin has been carefully selected to be non-toxic to animals.

20 Preferably the binding domain binds carbohydrate, which is present on the extracellular side of all eucaryotic cell membrane in the form of glycolipids and glycoproteins. The binding domain will thus serve to anchor the toxin at a site of action in wide variety of cells.

25 Preferably the cells form part of the pest gut epithelia.

It is preferred that the toxin actually be immobilised at the site of action, but even if actual (irreversible)
30 immobilisation does not occur, the use of the heterologous binding domain will still act to increase the effective concentration of the toxin at its site of action at the cell membrane.

35 In one embodiment of this aspect the binding domain consists of all or part of a lectin. Lectins are well known in the art for their ability to bind tightly to carbohydrate, different

lectins generally having particular affinities for different sugar residues. Particularly desirable are domains with galactose or galactosyl affinity, which would allow very widespread binding within the target pest class.

5

Preferably the lectin is a type two ribosome inactivating protein, and the (non-toxic) B chain is used. Examples of this type include:

10

- (a) *Abrus precatorius* (Abrin)
- (b) *Viscum album* (Viscumin)
- (c) *Adenia digitata* (Modeccin)
- (d) *Adenia volkensii* (Volkensin)

15

A table listing the origin and the properties of the four examples above is given (Stirpe, et al., 1992. Ribosome-inactivating proteins from plants: present status and future prospects. Bio/Technology, vol.10, 405-412; Barbieri, et al., 1993. Ribosome-inactivating proteins from plants. Biochemica et Biophysica Acta, vol.1154, 237-282).

20

Most preferably the ricin toxin B chain gene, derived from the ricin toxin, is used in the nucleic acid. Ricin is a toxic glycoprotein comprising two polypeptide chains, A and B, linked by a disulfide bond (32).

25

The binding of the B-chain to galactosyl terminated residues on cell surfaces is accomplished by two galactose binding domains located at either end of the peptide (34). Each of the two binding sites is capable of binding galactose and more complex sugars in the absence of the other site with no significant decrease in affinity for the ligand (35).

30

It has been shown that double lectin site ricin B chain mutants expressed in insect cells have residual galactose binding: evidence for more than two lectin sites on the ricin toxin B chain. Bioconjugate, Chem. vol.7, 651-658; Ferrini,

35

- et al., 1995. Expression of functional ricin B chain using the baculovirus system. *Eur. J. Biochem.* vol.233, 772-777). This suggests that other cell-surface binding sites may exist. One possibility is that mannose side chains on the ricin B chain itself interact with mannose receptors on the cell surface (see Newton et al (1992) *J Biol Chem* 267(17): 11917-11922; Frankel et al (1997) *Carbohydrate Research* 300,3: 251-258).
- 10 The binding of its B-chain to the cell surface, for instance to a glycoconjugate having non-reducing terminal galactose residue, causes or facilitates the internalisation of ricin into the cell. Internalisation may be via endocytic uptake in both coated and uncoated pits (see Frankel et al (1996) Protein Engineering 9,4: 371-379; Magnusson and Berg (1993) *Biochem J* 291: 749-755). Following routing and release of the free A-chain into the cytosol, cellular protein synthesis in eukaryotic cells is inhibited through the cleavage of a single adenine residue from eucaryotic 28 S RNA in the 60S ribosomal subunit (33). Several recent reports support a broad role for ricin toxin B chain; the polypeptide is thought not only to interact with cell surface galactose residues, but it may also be involved in the intracellular trafficking of the ricin toxin (44). Many receptors that recycle through endosomal vesicles to the cell surface pass through the trans-Golgi network. Within cells, the Golgi has the densest concentration of ricin binding sites, probably reflecting the concentration of galactosyltransferases in this cellular compartment (45). Ricin toxin entering cells by interacting with galactose-terminated receptors has been observed to concentrate in the Golgi region (45).

Although recombinant B chain lectin derivatives have been prepared in the past, this has generally been for therapeutic applications, in order to enhance the toxicity of the A chain. Thus it has been observed in many experiments that immunotoxins constructed with the ricin toxin B and A chain

together are consistently more toxic than those constructed with, for example, ricin toxin A chain alone (see e.g. Vitetta, et al., 1991 Sem. Cell Biol. vol.2, 47-58; Timar, et al., 1991 Br. J. Cancer, vol.64, 655-662; Embleton, et al., 1991 Br. J. Cancer vol.63, 670-674).

Thus a second aspect of the invention is a nucleic acid molecule comprising

- (i) a sequence encoding all or part of Bt cry polypeptide, and
- (ii) a sequence encoding all or part of a lectin.

Nucleic acid molecules and their encoded polypeptide products according to the present invention may be provided isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or free or substantially free of nucleic acid or genes of the species of interest or origin other than the sequence encoding a polypeptide with the required function.

20

Nucleic acid according to the present invention may include cDNA, RNA, genomic DNA and may be wholly or partially synthetic.

25 The term "isolated" encompasses all these possibilities. Where a DNA sequence is specified, e.g. with reference to Seq ID Nos 1-11 of Figure 3(a)-(k), unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed, as are degeneratively equivalent and complementary sequences.

30

Preferably the Bt cry toxin-encoding portion of the nucleic acid molecule comprises all or part of Seq ID No 1 (CryIA(b)) or Seq ID No 2 (CryIA(c)).

35

Preferably the lectin-encoding portion of the nucleic acid molecule comprises all or part of Seq ID No 3 (RTB1), Seq ID

No 4 (RTB2) or Seq ID No 5 (RTB3); these were derived from ricin toxin B chain as described below, but included mutations to introduce restriction sites.

- 5 Preferably the nucleic acid molecule comprises the CryIA-RTB combination shown in any one of Seq ID No 6 (CryIA(b)-RTB1); Seq ID No 7 (CryIA(b)-RTB2); Seq ID No 8 (CryIA(b)-RTB3); Seq ID No 9 (CryIA(c)-RTB1); Seq ID No 10 (CryIA(c)-RTB2); or Seq ID No 11 (CryIA(c)-RTB3).

10

It should be stressed that the invention also extends to nucleic acids encoding variants of naturally occurring toxin and binding molecules, which may for instance be mutants or other derivatives of such molecules. In particular nucleic acids having modified sequences based on Seq ID Nos 1 to 11 are included.

15

In each case the variant encodes a toxin or binding product either of which is homologous to a naturally occurring sequence (e.g. Bt Cry or a lectin) and retains the appropriate functional characteristic of that product (e.g. toxicity or the ability to bind glycosylation respectively).

20

Similarity or homology may be as defined and determined by the TBLASTN program, of Altschul et al. (1990) *J. Mol. Biol.* 215: 403-10, which is in standard use in the art, or, and this may be preferred, the standard program BestFit, which is part of the Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA, Wisconsin 53711).

25

Homology may be at the nucleotide sequence and/or amino acid sequence level. Preferably, the nucleic acid and/or amino acid sequence shares about 50%, or 60%, or 70%, or 80% homology, most preferably at least about 90%, 95%, 96%, 97%, 98% or 99% of the sequence upon which the variant is based (e.g. the natural sequence, or any one Seq ID Nos 1 to 11).

30

35

Homology may be over the full-length of the relevant sequence or may more preferably be over a contiguous sequence of about or greater than about 20, 25, 30, 33, 40, 50, 67, 133, 167, 200 or more amino acids (or codons) compared with the relevant amino acid sequence or nucleotide sequence as the case may be.

Thus a variant sequence in accordance with the present invention may encode, for instance within the (hybrid sequences, Seq ID Nos 6 to 11) a single amino acid change with respect to those sequences, or 2, 3, 4, 5, 6, 7, 8, or 9 changes, about 10, 15, 20, 30, 40 or 50 changes, or greater than about 50, 60, 70, 80 or 90 changes. In addition to one or more changes within the amino acid sequence encoded by the depicted sequences, an encoded variant amino acid sequence may include additional amino acids at the C-terminus and/or N-terminus. Naturally, changes to the nucleic acid which make no difference to the encoded amino acid sequence (i.e. 'degeneratively equivalent') are included.

Homology may be assessed using hybridization technology (52) for instance using a hybridization solutions comprising: 5X SSC (wherein 'SSC' = 0.15 M sodium chloride; 0.15 M sodium citrate; pH 7), 5X Denhardt's reagent, 0.5-1.0% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide.

One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology is (52):

$$T_m = 81.5^{\circ}\text{C} + 16.6\text{Log} [\text{Na}^+] + 0.41 (\% \text{ G+C}) - 0.63 (\% \text{ formamide}) - 600/\# \text{bp in duplex}$$

As an illustration of the above formula, using $[\text{Na}^+] = [0.368]$ and 50-% formamide, with GC content of 42% and an average probe size of 200 bases, the T_m is 57°C. The T_m of a DNA duplex decreases by 1 - 1.5°C with every 1% decrease in

homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42°C.

5 Particularly useful for certain applications e.g. expression in plants, may be alteration of codon usage (i.e. degeneratively neutral mutation) in order to assist expression. For instance, the AU/GC ratio for Cry genes deviates significantly from values found for plant coding
10 regions and well expressed reporter genes like *nptII*, *bar*, *gus* and *cat* (24). A plant coding region typically has an AU content of about 40-50 %, whereas the CryI coding regions have an AU content of 60-64 %, exceeding in some regions 70 % (24). Also, the codon usage of the Cry-coding sequence is
15 very unlike the preferred plant codon usage (25). There are clusters of unfavourable codons at several sites. Altering the codon usage may enhance efficient translation and elongation thus rendering the mRNA more stable to cytoplasmic Rnase activities (23, 26).

20 The mutants as described herein will have the enhanced binding properties discussed above.

One possible mode of analysis for mutants or other
25 derivatives is by transformation to assess function on introduction into a host cell capable of expressing the nucleic acid of the invention, and the subsequent comparison of the viability of that cell with cells transformed with other nucleic acids. Methodology for such transformation and
30 analysis, exemplified using SF21 insect cells, is described in more detail below. Another method comprises the use of transgenic plants expressing the mutant or derivative.

Methods for producing such a mutant or derivatives as
35 disclosed above embrace any method familiar to those skilled in the art.

Thus a further aspect is a method of producing a nucleic acid encoding a pesticidal fusion polypeptide comprising the step of combining a nucleic acid encoding a toxin with a nucleic acid encoding a heterologous binding domain, wherein said binding domain is capable of binding non-specifically to a cell membrane without disrupting it.

Optionally this method may include, or be preceded by, steps whereby changes to the sequence of the toxin or binding domains are made such as to produce a mutant or derivative, which may be by way of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid, leading to the addition, insertion, deletion or substitution of one or more amino acids in the encoded polypeptide.

Changes may be desirable for a number of reasons, including introducing or removing the following features: restriction endonuclease sequences; other sites which are required for post translation modification; cleavage sites in the encoded polypeptide; motifs in the encoded polypeptide for glycosylation, lipoylation etc. Leader or other targeting sequences may be added to the expressed protein to determine its location following expression. All of these may assist in efficiently cloning and expressing an active polypeptide in recombinant form (as described below).

Other desirable mutation may be random or site directed mutagenesis in order to alter the activity (e.g. specificity) or the affinity or stability of the encoded polypeptide.

As is well-understood, polypeptide homology is judged in terms of amino acid similarity or identity (in this case with respect to the altered toxin domain and/or binding domain).

Similarity allows for conservative variation, i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the

substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. As is well known to those skilled in the art, altering the primary structure of a polypeptide by a conservative substitution may not significantly alter the activity of that peptide because the side-chain of the amino acid which is inserted into the sequence may be able to form similar bonds and contacts as the side chain of the amino acid which has been substituted out. This is so even when the substitution is in a region which is critical in determining the peptides conformation.

Also included are homologs having non-conservative substitutions. As is well known to those skilled in the art, substitutions to regions of a peptide which are not critical in determining its conformation may not greatly affect its activity because they do not greatly alter the peptide's three dimensional structure. In regions which are critical in determining the peptides conformation or activity such changes may confer advantageous properties on the polypeptide. Indeed, changes such as those described above may confer slightly advantageous properties on the peptide e.g. yet further improved toxicity or host-range.

In one aspect of the present invention, the nucleic acid described above is in the form of a recombinant and preferably replicable vector.

"Vector" is defined to include, inter alia, any plasmid, cosmid, phage or *Agrobacterium* binary vector in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable, and which can transform prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication). Particularly favoured for some applications are BAC or BiBAC vectors.

Specifically included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from actinomycetes and related species, bacteria and eucaryotic
5 (e.g. higher plant, mammalian, yeast or fungal cells).

A vector including nucleic acid according to the present invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to
10 introduce the nucleic acid into cells for recombination into the genome.

Preferably, however, the nucleic acid in the vector is under the control of, and operably linked to, an appropriate
15 promoter or other regulatory elements for transcription in a host cell such as a microbial, e.g. bacterial, or plant cell. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and
20 in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell

By "promoter" is meant a sequence of nucleotides from which
25 transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA).

"Operably linked" means joined as part of the same nucleic
30 acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.

35 Thus this aspect of the invention provides a gene construct, preferably a replicable vector, comprising a promoter operatively linked to a nucleotide sequence provided by the

present invention as described above, such as the Seq ID no 9, 10 or 11.

5 Generally speaking, those skilled in the art are well able to construct vectors and design protocols for recombinant gene expression. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other
10 sequences as appropriate. For further details see, for example, *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et al, 1989, Cold Spring Harbor Laboratory Press.

15 Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis (see above), sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Current Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John
20 Wiley & Sons, 1992. The disclosures of Sambrook et al. and Ausubel et al. are incorporated herein by reference. Specific procedures and vectors previously used with wide success upon plants are described by Bevan (Nucl. Acids Res. 12, 8711-8721 (1984)) and Guerineau and Mullineaux (1993)
25 (Plant transformation and expression vectors. In: *Plant Molecular Biology Labfax* (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148).

30 Particular of interest in the present context are insect-cell vectors (e.g. based on baculovirus) and plant vectors.

Suitable promoters which operate in plants include the Cauliflower Mosaic Virus 35S (CaMV 35S) gene promoter that is expressed at a high level in virtually all plant tissues
35 (Benfey et al, 1990a and 1990b); the cauliflower meri 5 promoter that is expressed in the vegetative apical meristem

as well as several well localised positions in the plant body, e.g. inner phloem, flower primordia, branching points in root and shoot (Medford, 1992; Medford et al, 1991) and the *Arabidopsis thaliana* LEAFY promoter that is expressed very early in flower development (Weigel et al, 1992). Other promoters include the rice actin promoter.

In one embodiment of this aspect of the present invention provides a gene construct, preferably a replicable vector, comprising an inducible promoter operatively linked to a nucleotide sequence provided by the present invention.

The term "inducible" as applied to a promoter is well understood by those skilled in the art. In essence, expression under the control of an inducible promoter is "switched on" or increased in response to an applied stimulus. The nature of the stimulus varies between promoters. Some inducible promoters cause little or undetectable levels of expression (or no expression) in the absence of the appropriate stimulus. Other inducible promoters cause detectable constitutive expression in the absence of the stimulus. Whatever the level of expression is in the absence of the stimulus, expression from any inducible promoter is increased in the presence of the correct stimulus. The preferable situation is where the level of expression increases upon application of the relevant stimulus by an amount effective to alter a phenotypic characteristic. Thus an inducible (or "switchable") promoter may be used which causes a basic level of expression in the absence of the stimulus which level is too low to bring about a desired phenotype (and may in fact be zero). Upon application of the stimulus, expression is increased (or switched on) to a level which brings about the desired phenotype.

A suitable inducible promoter may be the GST-II-27 gene promoter which has been shown to be induced by certain

- chemical compounds which can be applied to growing plants. The promoter is functional in both monocotyledons and dicotyledons. It can therefore be used to control gene expression in a variety of genetically modified plants,
- 5 including field crops such as canola, sunflower, tobacco, sugarbeet, cotton; cereals such as wheat, barley, rice, maize, sorghum; fruit such as tomatoes, mangoes, peaches, apples, pears, strawberries, bananas, and melons; and vegetables such as carrot, lettuce, cabbage and onion. The
- 10 GST-II-27 promoter is also suitable for use in a variety of tissues, including roots, leaves, stems and reproductive tissues. Other promoters include the potatin promoter (tubers) and the ubiquitin promoter (wheat embryos).
- 15 The promoter may include one or more sequence motifs or elements conferring developmental and/or tissue-specific regulatory control of expression.
- Particularly advantageous in the present context may be an
- 20 inducible promoter which is switched on in response to elicitors, or other plant signals which are triggered during predation. This system may assist in reducing the likelihood of resistance in feeding-pests over long periods owing to selection pressure which is brought to bear by constitutively
- 25 toxic plants.
- The present invention also provides methods comprising introduction of such constructs into a plant cell and/or induction of expression of a construct within a plant cell,
- 30 by application of a suitable stimulus, an effective exogenous inducer.
- The vectors described above may be introduced into hosts by any appropriate method e.g. conjugation, mobilisation,
- 35 transformation, transfection, transduction or electroporation, as described in further detail below.

In a further aspect of the invention, there is disclosed a host cell containing nucleic acid or a vector according to the present invention, especially a plant, insect or a microbial cell.

5

Plants cells transformed with the DNA segment containing the sequence may be produced by standard techniques which are well known to those skilled in the art.

10 Thus DNA can be transformed into plant cells using any suitable technology, such as a disarmed Ti-plasmid vector carried by *Agrobacterium* exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711 - 87215
15 1984), particle or microprojectile bombardment (US 5100792, EP-A-444882, EP-A-434616) microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) *Plant Tissue and Cell Culture*, Academic Press), electroporation (EP 290395, WO 8706614 Gelvin Debeyser) other forms of direct DNA uptake (DE 4005152, WO 9012096, US 4684611), liposome
20 mediated DNA uptake (e.g. Freeman et al. *Plant Cell Physiol.* 29: 1353 (1984)), or the vortexing method (e.g. Kindle, *PNAS U.S.A.* 87: 1228 (1990d) Physical methods for the transformation of plant cells are reviewed in Oard, 1991, *Biotech. Adv.* 9: 1-11.

25

Agrobacterium transformation is widely used by those skilled in the art to transform dicotyledonous species. Recently, there has been substantial progress towards the routine production of stable, fertile transgenic plants in almost all
30 economically relevant monocot plants (Toriyama, et al. (1988) *Bio/Technology* 6, 1072-1074; Zhang, et al. (1988) *Plant Cell Rep.* 7, 379-384; Zhang, et al. (1988) *Theor Appl Genet* 76, 835-840; Shimamoto, et al. (1989) *Nature* 338, 274-276; Datta, et al. (1990) *Bio/Technology* 8, 736-740; Christou, et al.
35 (1991) *Bio/Technology* 9, 957-962; Peng, et al. (1991)

- International Rice Research Institute, Manila, Philippines 563-574; Cao, et al. (1992) *Plant Cell Rep.* 11, 585-591; Li, et al. (1993) *Plant Cell Rep.* 12, 250-255; Rathore, et al. (1993) *Plant Molecular Biology* 21, 871-884; Fromm, et al. (1990) *Bio/Technology* 8, 833-839; Gordon-Kamm, et al. (1990) *Plant Cell* 2, 603-618; D'Halluin, et al. (1992) *Plant Cell* 4, 1495-1505; Walters, et al. (1992) *Plant Molecular Biology* 18, 189-200; Kozziel, et al. (1993) *Biotechnology* 11, 194-200; Vasil, I. K. (1994) *Plant Molecular Biology* 25, 925-937; Weeks, et al. (1993) *Plant Physiology* 102, 1077-1084; Somers, et al. (1992) *Bio/Technology* 10, 1589-1594; WO92/14828). In particular, *Agrobacterium* mediated transformation is now emerging also as an highly efficient alternative transformation method in monocots (Hiei et al. (1994) *The Plant Journal* 6, 271-282).

Microprojectile bombardment, electroporation and direct DNA uptake are preferred where *Agrobacterium* is inefficient or ineffective. Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, e.g. bombardment with *Agrobacterium* coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with *Agrobacterium* (EP-A-486233).

The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person practising the invention with a particular methodology of choice. It will be apparent to the skilled person that the particular choice of a transformation system to introduce nucleic acid into plant cells is not essential to or a limitation of the invention, nor is the choice of technique for plant regeneration.

If desired, selectable genetic markers may be used consisting of chimeric genes that confer selectable phenotypes such as resistance to antibiotics such as kanamycin, hygromycin, phosphinotricin, chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate.

A number of plants that have been transformed with Bt genes have been reported in the art. In particular, transgenic maize resistant to extremely high and repeated infestations with the European corn borer were obtained using a synthetic version of CryIA(b) (27). Transformation with the native Bt gene had failed to effect production of detectable levels of protein whereas raising the G-C content from 38% to 65% produced a gene which is highly expressed in maize (27). This CryIA(b) gene has about 65% homology at the nucleotide level with the native gene and is designed to resemble a maize gene in terms of codon usage (27). Thus in those aspects of the present invention in which the pesticidal-fusion genes are introduced into plants for expression, it may be desirable to correspondingly alter the codon usage as described in (27) in order to increase polypeptide yield.

Thus a further aspect of the present invention provides a method of transforming a plant cell involving introduction of a vector of the present invention into a plant cell and causing or allowing recombination between the vector and the plant cell genome to introduce the sequence of nucleotides into the genome.

The invention further encompasses a host cell transformed with nucleic acid or a vector according to the present invention, especially a plant or a microbial cell. In the transgenic plant cell (i.e. transgenic for the nucleic acid in question) the transgene may be on an extra-genomic vector or incorporated, preferably stably, into the genome. There may be more than one nucleotide sequence per haploid genome.

Thus in one embodiment of this aspect of the invention there is provided a plant cell having incorporated into its genome nucleic acid of the present invention, under operative control of a regulatory sequence for control of expression.

- 5 The coding sequence may be operably linked to one or more regulatory sequences which may be heterologous or foreign to the pesticidal fusion polypeptide gene i.e. not naturally associated with either part of the gene for its expression. The nucleic acid according to the invention may be placed
10 under the control of an externally inducible gene promoter to place expression under the control of the user.

- Generally speaking, following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf
15 discs, as is standard in the art. Almost any plant can be entirely regenerated from cells, tissues and organs of the plant. Available techniques are reviewed in Vasil et al., *Cell Culture and Somatic Cell Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications*,
20 Academic Press, 1984, and Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989.

- The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed
25 in Shimamoto, K. (1994) *Current Opinion in Biotechnology* 5, 158-162.; Vasil, et al. (1992) *Bio/Technology* 10, 667-674; Vain et al., 1995, *Biotechnology Advances* 13 (4): 653-671; Vasil, 1996, *Nature Biotechnology* 14 page 702).

- 30 In addition to the regenerated plant, the present invention embraces all of the following: a clone of such a plant, seed, selfed or hybrid progeny and descendants (e.g. F1 and F2 descendants) and any part of any of these, such as cuttings, seed.

- 35 The invention also provides a plant propagule from such a

plant, that is any part which may be used in reproduction or propagation, sexual or asexual, including cuttings, seed and so on.

- 5 A plant according to the present invention may be one which does not breed true in one or more properties. Plant varieties may be excluded, particularly registrable plant varieties according to Plant Breeders' Rights. It is noted that a plant need not be considered a "plant variety" simply
10 because it contains stably within its genome a transgene, introduced into a cell of the plant or an ancestor thereof.

The invention further provides a method of influencing or affecting the toxicity of a plant to a pest including causing
15 or allowing expression of a pesticidal fusion polypeptide gene as discussed above within cells of the plant.

The invention further provides a method of including expression from a nucleic acid of the present invention (e.g.
20 as shown in Fig 3, or a mutant, allele or derivative of that sequence) within cells of a plant (thereby producing the encoded polypeptide), following an earlier step of introduction of the nucleic acid into a cell of the plant or an ancestor thereof. Such methods will influence or affect
25 the resistance which the plant has to the particular pest. Preferably the plant will be immune to the pest i.e. the pest will not consume or injure the plant under any known conditions. Alternatively resistance may be high or low (i.e. damage is below average) with respect to untransformed
30 plants.

Naturally the present invention also encompasses the expression product of any of the nucleic acid sequences disclosed and methods of making the expression product by
35 expression from encoding nucleic acid therefore under suitable conditions, which may be in suitable host cells.

- Following expression, the product may be isolated from the expression system (e.g. microbial) and may be used as desired, for instance in formulation of a composition including at least one additional component (e.g. carrier liquid). Such insecticidal compositions may be employed, for instance as sprays, particularly in situations which are analogous to those in which the toxin component of the fusion protein may have been employed previously.
- 10 Thus a plant or other commodity susceptible to attack by pests treated with such a composition also forms part of the present of the present invention.

- Alternatively the polypeptide product may perform its function *in vivo*, or *in situ* as described above.
- 15

- Thus the invention also embraces a method of controlling pests comprising the use of a polypeptide of the present invention (or composition, or host cell comprising it), particularly a method of killing pests comprising the administration, or causing or allowing the ingestion, of the polypeptide (or composition, or host cell comprising it) to the pests.
- 20

- The purified polypeptides of the invention, may be used to raise antibodies employing techniques which are standard in the art. Antibodies and polypeptides comprising antigen-binding fragments of antibodies may be used e.g. in assays for the polypeptide, or for labelling it.
- 25

- Methods of producing antibodies include immunising a mammal (e.g. human, mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and might be screened, preferably using binding of antibody to antigen of interest.
- 30
- 35

- For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, 1992, Nature 357: 80-82). Antibodies may be polyclonal or monoclonal. Antibodies may be modified in a number of ways. Indeed the
- 5 term "antibody" should be construed as covering any specific binding substance having a binding domain with the required specificity. Thus, this term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an
- 10 immunoglobulin binding domain, whether natural or synthetic. Chimaeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. Cloning and expression of Chimaeric antibodies are described in EP-A-0120694 and EP-A-0125023.
- 15 It has been shown that fragments of a whole antibody can perform the function of binding antigens. Examples of binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CH1 domains; (ii) the Fd fragment consisting of
- 20 the VH and CH1 domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al., Nature 341, 544-546 (1989) which consists of a VH domain; (v) isolated CDR regions; (vi) F(ab')₂ fragments, a bivalent fragment comprising two linked
- 25 Fab fragments (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site (Bird et al, Science, 242, 423-426, 1988; Huston et al, PNAS USA, 85, 5879-5883, 1988); (viii) bispecific
- 30 single chain Fv dimers (PCT/US92/09965) and (ix) "diabodies", multivalent or multispecific fragments constructed by gene fusion (WO94/13804; P Holliger et al Proc. Natl. Acad. Sci. USA 90 6444-6448, 1993).
- 35 Diabodies are multimers of polypeptides, each polypeptide comprising a first domain comprising a binding region of an immunoglobulin light chain and a second domain comprising a

binding region of an immunoglobulin heavy chain, the two domains being linked (e.g. by a peptide linker) but unable to associate with each other to form an antigen binding site: antigen binding sites are formed by the association of the
 5 first domain of one polypeptide within the multimer with the second domain of another polypeptide within the multimer (WO94/13804).

As an alternative or supplement to immunising a mammal, antibodies with appropriate binding specificity may be
 10 obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces;
 15 for instance see WO92/01047.

In a yet further aspect of the present invention there is disclosed a method of assessing the toxicity of a polypeptide to a particular species comprising:
 20 (i) introducing a nucleic acid encoding said polypeptide into a host cell from that species,
 (ii) causing or allowing the nucleic acid to be expressed in a host cell from that species,
 (iii) observing the viability of the cell and
 25 correlating the results of the observation with the toxicity of the polypeptide.

The introduction and expression of the toxin can be carried out as described above. Preferably a well characterised
 30 promoter is used in order to minimise any variation in transcription. The viability can be assessed by any method known in the art, possibly only by visual observation alone, or using EM observation. However, in preferred embodiments, the method comprises use of an assay which assesses esterase
 35 activity or membrane integrity, for instance an assay based on the Ethidium homodimer 1, Calcein AM or trypan blue (see Molecular Probes, product Information sheet,

5

10 Membrane integrity assays may be particularly useful for
assaying toxins (e.g. Bt cry-based toxins) which are thought
to act on membranes.

Thus in the present context the polypeptide may be the
20 pesticidal polypeptide described above. The host cell will be
from an appropriate pest e.g. an insect cell.

Baculoviruses are particularly effective vectors for use in this method because protein synthesis using these vectors is temporal (Miller (1988) Ann Rev Microbiol 42:177-199). Other things being equal the protein concentration in the control and experimental cells will increase steadily with concomitant toxic effect, the severity of which will be determined by the LC_{50} of the protein.

The invention will now be further illustrated with reference

to the following non-limiting Figures and Examples. Other embodiments falling within the scope of the invention will occur to those skilled in the art in the light of these.

5 FIGURES

Figure 1 - Constructs expressed in Sf21 cells and transgenic rice plants. (A) Site-directed mutagenesis of the ricin toxin B-chain (RTB) to derive 3' terminal fragments spanning the
10 galactose-binding domains (green boxes). Mismatched oligonucleotides LF1, LB1, LB2 and LB3 were used to introduce novel EcoRI (LF1) and HindIII (LB1, LB2, and LB3) sites. Three RTB fragments were obtained and called RTB1, RTB2 and RTB3. (B) Schematic diagrams of the control and fusion
15 cassettes. Bt *cry1Ab* and *cry1Ac* sequences are shown as orange boxes, and RTB fragments as thick lines. Constructs pB and pC were Bt controls, constructs pR1, pR2 and pR3 were RTB controls, and pBR1, pBR2, pBR3, pCR1, pCR2 and pCR3 were fusion constructs. Restriction sites are shown for pBR1 only
20 but apply to all constructs. Sites are abbreviated as follows: B = *Bam*HI, Ec = *Eco*RI, Eh = *Ehe*I, H = *Hind*III. (C) For expression in transgenic plants, the 11 constructs were cloned in the vector pAC76 containing the maize ubiquitin-1 promoter and first intron, and the nos terminator.
25 Restriction sites are abbreviated as follows: Eh = *Ehe*I, H = *Hind*III, S = *Sma*I.

Figure 2 - Survival, growth and development of stem borer larvae feeding on transgenic rice stems and controls. Graph
30 showing mean insect survival \pm SE after 4 days (initial inoculum of six neonate larvae). Each value represents the mean of four replicate bioassays, except the control, which represents six replicate bioassays.

35 Figure 3 (a) to (k) - This shows the nucleotide sequences of CryIA (b&c), the ricin toxin B chain gene fragments and the

fusion genes cloned in pFASTBAC1 under the control of the polyhedrin promoter. The sequences are labelled Seq ID Nos 1-11. All sequence read 5'-3' direction. The codon ATG starting at nucleotide 97 is the translation initiation site for the genes CryIA(b&c) and all the fusion genes. For the ricin toxin B chain fragments the codon ATG starting at nucleotide position 125 serve as the translation initiation site. All the genes are terminated by the SV40 polyadenylation sequence. The stop codons TAG and TAA are employed and their positions (if sequences are read in the 5'-3' direction) vary with the size of each gene. If the sequences are read from the 3'-5' direction the two codons TAG and TAA are located at nucleotide positions 17 and 7 respectively.

15

EXAMPLES

Materials. All restriction endonucleases, T₄ ligase and all restriction enzymes were obtained from Boehringer Mannheim (U.K.). The QUIAGEN plasmid kit and the QUIAquick gel extraction kit were acquired from QUIAGEN. The pGEM-T cloning vector was purchased from Promega (U.K.). The Ethidium homodimer 1 and Calcein AM were purchased from Molecular probes Europe BV (Netherlands). The pFASTBAC1 baculovirus transfer vector, the TC-100 insect cell culture dishes and media, fetal calf serum, cellfectin and the DH10BAC competent cells were purchased from GIBCO BRL (U.K.). The ricin toxin B chain gene (plasmid pWBT) and the anti-ricin toxin B chain antibodies used in this research were kindly given by Dr. L. Roberts of Warwick University. The plasmids pUBB and pUBC containing the CryIA(b) and CryIA(c) genes were kindly given by Dr. I. Altosaar of the University of Ottawa, Canada and were as described (Sardana, et.al.,1996). All primers used were synthesised at Genosys Biotechnologies (England).

35

Example 1: preparation of toxin gene

31

Site directed mutagenesis of ricin toxin B chain gene. Four mutagenic oligonucleotides were used in PCR reactions to create an *EcoRI* and a *HindIII* restriction site at selected positions along the ricin toxin B chain gene in the plasmid pWT (Wales et.al., 1991) - these are shown in Fig 1A. The five mutagenic oligonucleotides (mutated bases underlined) were:

LF1=5' CAACAACAAAGGAATTCATGCTGATG 3'
 LB1=5' GGACACACACACTGCAAGCTTTGTAATC 3'
 LB2=5' CGGATCCGAAAAGCTTCACATCTAACAC 3'
 LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3'

PCR mutagenesis was carried out in a 50 ml total volume containing 1x PCR buffer (Boehringer Mannheim), 200 mM each dNTP, 15 mM MgCl₂, 300 nM each primer, 2.6 units enzyme mix (Boehringer Mannheim) and 70 ng pBWT plasmid DNA. After an initial denaturation step at 94°C for 2 min, 10 fixed amplification cycles were carried out (94°C, 15 s; 65°C, 30 s; 72°C, 1 min) followed by another progressively lengthening 20 cycles (94°C, 15 s; 65°C, 30 s; 72 °C, 1 min; elongation increasing by 5 s each cycle). A final extension step was carried out at 72°C for 7 min. PCR products were sized by 0.8% agarose gel electrophoresis, purified (QIA-quick gel extraction kit, Qiagen) and subcloned in the vector pGEM-T (Promega). Insert size and orientation was confirmed by digestion with *EcoRI* and *HindIII*.

Sequencing, to confirm the original RTB sequence, was carried out using M13/pUC19 primers (Gibco BRL) and the BIG DYE sequencing kit (Boehringer Mannheim). Cycling sequencing was carried out using the PTC-200 Peltier thermal cycler (M.J. Research Inc.).

35

Example 2: preparation of fusion in baculovirus vector

Overview of baculovirus system

The insect baculoviruses *Autographa californica* (Ac) and *Bombyx mori* nuclear polyhedrosis viruses (MNPV) had previously been shown to be versatile high level expression vectors of heterologous proteins (6,7,13,17). This is mainly due to the unique nature of the baculovirus replication cycle, which involves the sequential expression of virus encoded genes in four, temporary distinct phases (2, 7, 10, 18). The first three stages result in the production of infectious virus particles which invade other cells and therefore disseminate infection. In the final, very late phase of gene expression, starting at about 18 hours post infection, virus particles are occluded into crystalline proteinaceous structures called polyhedra (7). The polyhedrin gene is dispensable for the production of virus particles and can be replaced with foreign coding sequences (7, 27). Because the polyhedrin gene is expressed in the late phase of gene expression it can be replaced with sequences coding for toxic proteins without affecting viral infectivity.

Several insecticidal crystal toxins have been shown to be expressible in baculovirus infected insect cells. The complete insecticidal crystal protein gene *cryIA(b)* was cloned into AcNPV, replacing the polyhedrin gene (8). A full length and a truncated bacterial CryIVD mosquitocidal protein were also successfully expressed in lepidopteran cells using the baculovirus vector (11).

Cloning into pFASTBAC1 baculovirus transfer vector.

The *cryIAb* and *cryIAC* genes were excised from source plasmids (pUBB and pUBC (46) by digestion with *Bam*HI and *Eco*RI, and subcloned in the baculovirus transfer vector pFASTBAC Hb (Gibco). The recombinant plasmids were digested with *Eco*RI and *Hind*III allowing directional subcloning of the ricin gene

fragments. Six intermediate pFASTBAC Hb fusion constructs were generated, representing the two Bt genes each fused to one of the three RTB fragments. These were digested with *Eco47III* and *EcoRI* (*cry1Ab*) or *EcoRI* and *Xho I* (*cry1Ac*), and the termini were polished using mung bean nuclease, thus bringing the Bt and RTB coding regions in-frame upon re-ligation (Fig. 1). The recombinant plasmids were then digested with *StuI* and *HindIII*, allowing directional subcloning of the fusion constructs in the similarly digested vector pFASTBAC1, whose polylinker is flanked with Tn7 attachment sites. The pFASTBAC1 vector was also digested separately with *BamHI* and *EcoRI* or with *EcoRI* and *HindIII* to allow subcloning of the two unmodified Bt genes and the RTB fragments, respectively, as controls.

15

Site specific transposition.

Recombinant pFASTBAC1 transfer vectors were transformed into competent *Escherichia coli* cells of strain DH10BAC (Gibco BRL). These cells contain a modified baculovirus genome carrying a Tn7 attachment site, and a plasmid providing Tn7 transposase, allowing site-specific transposition of the cassettes cloned in pFASTBAC1 into the baculovirus genome. White colonies were isolated and from them high molecular weight DNA was purified as outlined (37).

Recombinant bacmids were confirmed using PCR and the M13/PUC19 primers. Five microlitres of a 10x PCR buffer, one microlitre of 10x dNTP mix, 1.25ul of a 10uM stock of each primer, 1.5 μ l of a 50mM $MgCl_2$, 2.5 μ l of a 1% solution of the detergent W-1, one microlitre of template DNA and 2.5 units of Taq polymerase were used in 50ul PCR reactions. After incubation at 93°C for three minutes 35 cycles of PCR were performed as follows: 94°C for 45 seconds, 55°C for 45 seconds and 72°C for five minutes (37). Ten microlitres of the

35

PCR reactions were electrophoresed on a 0.8% agarose gel.

Results of vector construction

5 Three terminal deletions of the ricin toxin B-chain gene were obtained. Digestion of the resultant pGEM-T recombinant vectors with the restriction enzymes EcoRI and HindIII yielded the expected three ricin toxin B chain gene deletions RTB1, RTB2 and RTB3. For RTB3 (480bp, AA1-AA139) primers
10 LFlxLB3 were used; RTB2 (739 bp, AA1-AA236) primers LFlxLB2 were used); and LB1 (841 bp, AA1-AA262) primers LFlxLB1 were used.

15 The three ricin toxin B chain fragments were then fused with the two Bt genes (using the EcoRI site of each gene) to achieve six different translation fusion proteins. The six translation fusion protein genes were confirmed through restriction enzyme digestion (results not shown).

20 The fusion genes were then transposed into the baculovirus genome under the control of the polyhedrin promoter. Success of site specific transposition was confirmed by PCR using the M13/PUC primers. The primers are directed towards the Tn7 attachment site of the baculovirus genome. A PCR reaction on
25 this region alone (without any construct) yields a 300 base pair fragment. If this region is transposed with a non recombinant pFASTBAC1 DNA, a PCR on this region using the M13/PUC19 primers yields a DNA fragment of 2 300 base pairs. The results of the PCR (not shown) confirm successful
30 transposition of the entire translation fusion protein gene expression cassettes as indicated by the corresponding increase of size in excess of 2 300 base pairs. These recombinant baculoviruses were then transfected into Sf21 insect cells. High molecular weight DNA extracted from
35 infected insect cells also confirmed (through PCR using the M13/PUC primers) the successful infection of the insect cells (results not shown).

Example 3: production of host cells expressing pesticidal fusion polypeptide

Transfection of Sf21 insect cells with recombinant bacmid DNA. One million Sf21 insect cells were seeded in a 35mm cell culture plate overnight in 2mls of TC-100 media supplemented with 10 % fetal calf serum. The cells were washed two times with serum and antibiotic free media and overlain with one ml of the transfection mix (5 microlitres recombinant bacmid DNA, 800 μ l serum and antibiotic free TC-100 media and six microlitres cellfectin) for five hours (37). After removal of the transfection mix the cells were then covered with complete TC-100 media (supplemented with 10% fetal calf serum) for 48 hours. The virus was harvested (first inoculum) in the supernatant and the cells overlain for a further 48 hours with two millilitres of complete media and the virus was harvested (second inoculum). The second supernatant was used as an inoculum in experiments to determine the optimum time of expression of the proteins. For all infections, media was aspirated from the cells and the cells overlain with 250 μ l of inoculum for one hour (m.o.=5). At the end of one hour the inoculum was discarded and the cells overlain with two millilitres of complete TC-100 media supplemented with 10% fetal calf serum. Protein expression was analysed over a period of 60 hours. At the end of each analysis period the cells were lysed using protein disruption buffer (62.5 mM Tris-HCl, 2% SDS). Fifteen microlitres of protein sample was then loaded on a 12.5% polyacrilamide gel and western blot analysis was done with either anti-ricin toxin B chain antibodies or anti-CryIA(c) antisera.

Result of western blot analysis for protein expression.

Baculovirus protein expression was analysed over a period of 60 h. Cell samples were collected at 2, 20, 24, 34, 48, and 60 hours p.i. and protein concentrations determined using the dye binding method (47). Protein samples (20 μ g) were

fractionated by 12.5% SDS-PAGE and transferred to nitrocellulose membranes (Hybond C; Amersham) using the Trans-Blot semidry transfer cell (Bio-Rad) according to the manufacturer's instructions. Filters were probed with antisera against CryIAb and CryIAc (Ms. S. Bano-Maqbool, Centre for Excellence in Plant Molecular Biology, Pakistan) or RTB (Dr. L. Roberts, University of Warwick, UK). We used alkaline phosphatase (AP)-conjugated anti-rabbit IgG (Fc) as the secondary antibody (Promega) and detection was carried out according to the supplier's recommendations.

For RTB1, RTB2 and RTB3 (control constructs containing only the ricin toxins fragments), protein expression started at about 20 hours post infection and increased gradually up to 60 hours, being optimised around 34 hours. Protein bands of lower molecular weight than expected, presumably representing degradation products, were detected at 48 hours (RTB1), 34 hours (RTB2) and 24 hours RTB3. Thus the third ricin toxin B chain gene deletion, RTB3, in particular, appears to be unstable and degrades after synthesis

As for the cryIA(a) and cryIA(c) genes together with the fusion proteins, degradation products were detected as early as 20 hours, suggesting that the proteins were sensitive to degradation in insect cells.

Example 4: In vitro toxicity assays

Determination of optimal fluorophore concentration.

Optimal dye concentrations vary with cell types. The following experiment was done to find out the lowest dye concentration that gives sufficient signal. Healthy growing cells were harvested into microfuge tubes and washed once with 1000 μ l of Dulbecco's phosphate buffered saline. Half of these cells were killed using 30% methanol for 30 minutes. Using samples of dead cells and live cells separately, an

aliquote of the cells were each incubated with a different concentration of the Ethidium homodimer 1 from 0.1-12.8 μM for 30 minutes. Separate samples of live and dead cells were also incubated with various levels of Calcein AM (0.1-12.8 μM). The stained cells were visualised under a conventional fluorescein microscope. A concentration of 6.8 μM of Ethidium homodimer 1 sufficiently labelled the nuclei of dead cells bright red. A concentration of 0.4 μM of Calcein AM sufficiently labelled live cells green. The two fluorophores were then mixed together to achieve a solution consisting of 6.8 μM Ethidium homodimer 1 and 0.4 μM Calcein AM in D-PBS and used to stain samples of dead and live cells. From these results it was concluded that the two fluorophores at the selected concentrations can be reliably used to assess the viability of infected cells.

Live/Dead viability/Cytotoxicity assays over 96 hours.

A million cells were seeded in 35 mm culture dishes overnight for each infection (seven replications each). The media was aspirated from the cells and the cells were overlain with 250 μl inoculum. Fourteen different infections carried out included:

- (a) insect cells mock infected with media
- (b) insect cells infected with non-recombinant baculovirus
- (c) insect cells infected with recombinant baculovirus containing the *gus* gene
- (d) insect cells infected separately with recombinant baculovirus containing the coding sequence of CryIA(b), CryIA(c), RTB1, RTB2 and RTB3.
- (e) insect cells infected separately with the six different fusion genes.

Infected cells were lysed and DNA extracted from them at 34 hours post infection. The composition of the lysis buffer and the method of extraction were according to King and Possee (38). This DNA was used to verify success of infection of the Sf21 insect cells in PCR reactions utilising the M13/PUC

primers. Infected cells from one culture dish for each infection were analysed for viability at 2, 24, 34, 48, 72 and 96 hours post infection. The cells were pelleted at 5 000 xg and washed once with sterile tissue culture-grade Dulbecco's phosphate-buffered saline (D-PBS). The cells were gently resuspended in 50 μ l of the live/dead assay reagent (6.8 μ M Ethidium homodimer 1 and 0.4 μ M Calcein AM, made up in D-PBS) and incubated at room temperature for 30 minutes. After the 30 minutes, 40 μ l of the assay reagent was removed from the cells and discarded. The cells if undisturbed, by now would have settled at the bottom of the microfuge tubes. The remaining 10 μ l, concentrated with cells was put on a microscope slide and photographed under the fluorescein microscope (485 \pm 11 nm) at a magnification of x400.

Ethidium homodimer-1 binds tightly to DNA and fluoresces deep red, but it is a hydrophilic molecule and cannot cross living cell membranes. Calcein AM is a neutral molecule that diffuses freely into cells. It is cleaved by intracellular esterase activity and fluoresces bright green. Ethidium homodimer-1 thus labels the nuclei of dead cells, whereas calcein AM labels the cytosol of living cells.

Two photograph sets, one for the Ethidium homodimer 1 fluorescence and the other for the Calcein AM fluorescence were taken by switching alternately the two filter sets so that each cell sample had a photograph showing the proportion of cells that are still alive (green fluorescence) and another showing the proportion of cells that are dead (red fluorescence).

Results of toxicity assays

When viewed under an inverted light microscope (x400) cells infected with the fusion proteins exhibited a number of symptoms of toxicity as early as 24 hours post infection. The symptoms included, floating in the media, large spherical

shapes and lysed cells. Some of the symptoms, particularly cell lysis, appeared later than 60 hours post infection in the control experiments. The controlled experiments included cells mock infected with media, cells infected with baculovirus only and cells infected with recombinant baculovirus containing the *gus* gene and the ricin toxin B cain gene fragments only. In the live/dead viability assays on the Sf21 insect cells infected with recombinant baculoviruses expressing different proteins, cells which gave green fluorescence had esterase activity and so were assessed as alive, while cells giving red fluorescence had compromised membranes and were assessed as dead.

The results of the assays can be summarised as follows:

- (a) the assay was tested with healthy Sf21 insect cells. Uninfected cells were left for 72 hours undisturbed and without change of media. Very few cells were observed dead when assessed as described above. When healthy cells were treated with 70% methanol for 30 mins all the cells were observed dead.
- (b) Sf21 insect cells infected with baculovirus only were assessed after 2 hrs, 24 hrs, 34 hrs and 72 hrs post infection. Many cells were still alive after 72 hours.
- (c) Sf21 insect cells expressing GUS activity were assessed after 2, 24, 34, 72 hrs post infection. Again many cells are still alive after 72 hrs.
- (d) Sf21 insect cells expressing CryIA(b) were assessed after 2, 24, 34, 72 hrs post infection. The cells were seriously affected by this protein between 34-72 hrs.
- (e) Sf21 insect cells expressing CryIA(c) were assessed after 2, 24, 34, 72 hrs post infection. Again the cells are also seriously affected by this protein between 23-72 hrs.

(f) Sf21 insect cells expressing RTB1 protein were assessed after 2, 24, 34, 72 hrs post infection. Many cells were still alive after 72 hrs.

- 5 (g) Sf21 cells expressing CryIA(b)-RTB1 fusion protein were assessed after 2, 24, 34, 72 hrs post infection. The cells were seriously affected between 24-34 hrs post infection.

- 10 (h) Sf21 cells expressing CryIA(c)-RTB1 fusion protein were assessed after 2, 24, 34, 72 hrs post infection. The cells were seriously affected between 24-34 hrs.

- 15 (i) Sf21 cells expressing RTB2 protein were assessed after 2, 24, 34, 72 hrs post infection. Many of the cells were still alive after 72 hrs.

- 20 (j) Sf21 cells expressing CryIA(b)-RTB2 protein were assessed after 2, 24, 34, 72 hrs post infection. By 24 hrs many cells are dead i.e. much earlier than in the above assays.

- 25 (k) Sf21 cells expressing CryIA(c)-RTB2 protein were assessed after 2, 24, 34, 72 hrs post infection. A significant number of the cells were dead by 24 hrs; again earlier than with the toxin alone.

- 30 (l) Sf21 cells expressing RTB3 protein after were assessed 2, 24, 34, 72 hrs post infection. Many cells were still alive after 72 hrs.

- (m) Sf21 cells expressing CryIA(b)-RTB3 fusion protein were assessed after 2, 24, 34, 72 hrs post infection. Many cells were dead by 24 hrs, although some cells survived until 72 hrs.

- 35 (n) Sf21 cells expressing CryIA(c)-RTB3 fusion protein were assessed after 2, 24, 34, 72 hrs post infection. Many of the

cells survived until 72 hrs.

Insect epithelial cell cultures are not natural targets for Bt d-endotoxins and their toxin sensitivities are several orders of magnitude lower than those observed in the insects from which they originate²³. However, cell cultures are routinely used to estimate the activity of Bt toxins against various insect species²⁴.

Although the most severe symptoms were observed in insect cells infected with fusion proteins containing RTB1 and RTB2, the fusion of any of the three different RTB fragments to either Cry1Ab or Cry1Ac resulted in greatly increased toxin sensitivity in Sf21 cells when assayed for viability using the Ethidium homodimer 1 and Calcein AM. Toxicity symptoms were observed at about 34 hours post infection. It is clear that the fusion proteins have severe cytotoxic effects on the insect cells producing them, and it is also clear that the addition of the glycosylation-binding (ricin toxin B chain) gene to the toxin enhances this toxicity, as measured by premature cell death and extensive cell lysis.

The choice of the toxins Cry1Ab and Cry1Ac and the use of Sf21 cells was based on earlier observations that Cry1Ab is moderately toxic to Sf9 and IPLB-Sf21 insect cells while Cry1Ac has no effect on these cells (42, 43). Clearly, the acquisition of toxicity by Cry1Ac when combined with the ricin toxin B-chain suggests a role for galactose-binding in the mediation of toxicity.

Example 5: Use of insecticidal fusions in plants

Fusion proteins may be transformed into plants, for instance maize or rice, as follows. The sequence encoding the fusion polypeptide is inserted into an expression cassette under the control of a ubiquitin promoter. Plants are transformed using particle bombardment (see e.g. Christenson et al (1992))

Plant Mol Biol 18:675-689; Christou et al (1991) Bio/Technol 16: 957-962). The plants may then be used in insect feeding bioassays to assess the toxicity of the fusions at the whole organism level and to measure resistance under conditions of varied selection pressure. Plants may also be assessed for transgene integration and expression patterns, and the expression product may be purified using standard protocols. An example with rice is given below.

10 *Overview of generation of Bt-transgenic rice plants*

Mature seed-derived embryogenic rice callus was transformed with the 11 constructs (six fusions and five controls) shown in Fig. 1B. Each construct was introduced into rice tissue by particle bombardment, along with a co-transformation vector allowing selection for hygromycin resistance. Further analysis was carried out on plants expressing equivalent amounts of the 11 recombinant proteins. The fusion proteins were expressed more efficiently in transgenic rice plants than in baculovirus-infected insect cells as were the unmodified Bt proteins.

Transgene constructs

25 The control and fusion protein cassettes described above were isolated from the intermediate pFASTBAC Hb vectors using *EheI* and *HindIII*, and directionally subcloned in pAL76 (an in-house ubiquitin promoter-based transformation vector) digested with *SmaI* and *HindIII* (Fig. 1C).

30

Particle bombardment and recovery of transgenic plants

Mature rice seeds (*Oryza sativa* L. cv Eyil05) were de-hulled and washed in 70% ethanol for 2 min. After rinsing twice in distilled water, the seeds were sterilised in 1.6 % sodium

35

hypochlorite for 30 minutes with gentle agitation, then rinsed three times in sterile distilled water. The seeds were germinated in darkness on rice callus induction medium (RCIM; MS basal medium supplemented with 2.5 mg l⁻¹ 2, 4-D and solidified with 2.5 g l⁻¹ phytagel). After 7 days, scutellum-derived callus was dissected from the germinating seeds and cultured in darkness on osmoticum medium (RCIM supplemented with 36 g l⁻¹ sorbitol and 36 g l⁻¹ mannitol (48) for 4 h. The callus was then bombarded with 0.95 mm diameter gold particles coated with DNA. Bombardment was carried out twice with a 4-h interval, and the callus was co-bombarded with one of the 11 plasmids containing fusion or control constructs and a cotransformation plasmid containing a marker conferring hygromycin resistance (49), at a molar ratio of 1:3. Particle coating and bombardment procedures were described earlier (50, 51). After the second bombardment, callus was incubated in darkness on the osmoticum medium for a further 16 h and then transferred to RCIM for three days. The callus was then transferred to selection medium (RCIM supplemented with 30 mg l⁻¹ hygromycin B) for 4 weeks. Subcultures were carried out at 2-week intervals. Hygromycin resistant callus was transferred to HRSM1 medium in daylight (MS basal medium supplemented with 30 g l⁻¹ maltose, 2 mg l⁻¹ BAP, 0.5 mg l⁻¹ NAA, 30 mg l⁻¹ hygromycin B and 5 g l⁻¹ gelrite gellan gum) to initiate shoot regeneration. After one week, the regenerating callus was transferred to HRSM2 medium (as HRSM1 but with only 2.5 g l⁻¹ gelrite gellan gum) and cultured under the same conditions. Fully regenerated shoot systems were transferred to rooting medium HRRM (½ MS basal medium supplemented with 10 g l⁻¹ sucrose). Mature plants were transferred to the glasshouse.

RT-PCR analysis

Total RNA was extracted from 100 mg leaf tissue of transformed and wild type rice plants using the RNeasy Plant Mini kit (Qiagen) according to the supplier's recommendations. RT-PCRs were carried out using the Access-

PCR kit (Promega) according to the manufacturer's instructions. We used 100 ng total RNA and 50 pmol of each primer. Primers CRF1 and CRR1 amplify both *cryIab* and *cryIac*, while primers RTF1 and RTR1 amplify the RTB gene fragment. The primer sequences were as follows: CRF1 (5'-CGCATTGAAAC CGGTTACTCTC CCA-3'), CRR1 (5'-CTTGGGCAGAACACCGAAGCTACC-3'), RTF1 (5'-GATGTTTGTATGGATCCTCAGCCCA-3') and RTR1 (5'-GCCGAACAATGGTTGTAA CAAAAGG-3').

Northern blots

Total RNA was extracted as described above, and 15 mg aliquots were fractionated by electrophoresis on 1% agarose-formaldehyde gels and transferred to nitrocellulose filters according to standard procedures (52). We labeled 1.8 kbp *Bam*HI/*Eco*RI fragments corresponding to the *cryIab* and *cryIac* coding regions, for use as probes.

Western blot analysis

Western blot analysis of transgenic plants was carried out on small leaf sections ground to a fine powder under liquid nitrogen. Samples were dispersed in protein extraction buffer (100 mM Tris.Cl pH 8.1, 100 mM 2-mercaptoethanol) and centrifuged at 12,000 x g for 10 min at 4°C. SDS-PAGE was carried out using 30 mg samples, and blotting and detection procedures were carried out as described above.

Analysis of banding patterns on western blots suggested that fusion proteins containing the longest RTB fragment (RTB1) were the most stable. The control RTB fragments were also efficiently expressed in transgenic rice plants. The presence of transgene mRNAs in the plants was confirmed by northern blot analysis and RT-PCR (data not shown).

Thus it is clear that the fusion proteins were efficiently expressed in transgenic rice plants.

Example 6: Insect bioassays

Overview of insect bioassays

Insect bioassays were performed using stem sections of wild type control plants and transgenic lines individually transformed with nine of the 11 constructs (six fusions and five controls) shown in Fig. 1B. Plants transformed with pR2 or pR3 (control constructs containing the shorter RTB fragments) were not tested. The effect of these control and fusion proteins was determined on an economically important rice pest, the striped stem borer.

Insect bioassays

A culture of striped stem borer eggs (*Chilo suppressalis*) was obtained from Dr M. Cohen, International Rice Research Institute, The Philippines. Eggs were maintained under a 27/25°C day/night temperature regime with a 16-h photoperiod. The insects were held under a MAFF licence EPHL 51/2595(3/1998). Rice plants were grown and maintained under identical conditions.

Bioassays were carried out on stem sections from primary transformants and wild type controls. A single stem section, 7 cm long with at least one node, was taken from each plant. Sections were placed on moist filter paper in dishes and infested with neonate stem borer larvae (<2 h old) by placing three at each end of the cut sections to facilitate entry into the stem. Four replicates were set up for each line, except the wild type control, where eight replicates were used. The dishes were then sealed with Parafilm and left for 4 days in a controlled growth chamber under the conditions specified above. After the trial period, stem sections were

dissected under a binocular microscope and insect survival, development and weight were recorded. Statistical analysis of insect data was performed with Statview software v. 5.0 (Abacus Concepts, CA). Analysis of variance (ANOVA) was used to test for significant differences between treatments. A rejection limit of $p > 0.05$ was used.

Results

The results are shown in Fig. 2. Insect survival on wild type control stem sections was >95%.

On plants expressing the unmodified CryIAb and CryIAC toxins, insect survival decreased to between 55 and 80% (mean values of 79% (CryIAb) and 71% (CryIAC)). The data suggested that CryIAC was slightly more toxic towards the stem borer than CryIAb, although the difference was not statistically significant. There was no significant effect on insect survival in line pR1, expressing the RTB1 control fragment, although surviving larvae showed impaired growth (see below).

With the exception of plants transformed with construct pBR3, the mean insect survival on all plants expressing fusion proteins was significantly lower than that of wild type control plants and plants expressing control proteins.

Plants transformed with constructs pCR1, pCR2 and pCR3 were highly resistant to the stem borer, with insect mortalities of 87%, 74% and 61% respectively.

The results for plants transformed with constructs pBR1, pBR2 and pBR3 were more variable, with survival in the range of 30-50%, and pBR2 the most effective.

Surviving larvae showed impaired growth and developmental arrest in all transgenic lines. Mean larval weight fell by

30% in plants expressing the control Bt proteins and the control RTB fragment. Developmental arrest was more severe in plants expressing CryIaC than in plants expressing CryIaB.

- 5 Of the CryIaB fusion proteins, only pBR1 had a significantly greater effect than the control Bt protein CryIaB, causing a 60% reduction in mean larval weight. Severe reductions in larval growth and development were also observed in plants expressing pCR1, pCR2 and pCR3. The results with pCR2 and
10 pCR3 were similar to those for pBR1, but pCR1 was again the most effective construct, causing a mean larval weight decrease of >80% and preventing development beyond the first instar.
- 15 Thus transgenic rice plants expressing the fusion proteins were fully protected against feeding by the striped stem borer, causing insect mortalities of 55-80% and poor growth and arrested development in surviving larvae. The most toxic fusion protein was pCR1. After four days there was 87%
20 insect mortality and developmental arrest at the first instar stage in surviving larvae. After four days, larvae feeding on wild type rice plants had reached the third instar and had caused severe damage to the stems. Conversely, larvae feeding on transgenic plants expressing the fusion proteins
25 did not cause significant damage. The addition of a galactose binding domain to the Bt toxins therefore significantly enhanced their activity against the striped stem borer.

30 *Conclusions*

- These Examples clearly show that a heterologous binding domain which is non-toxic *per se* but which is capable of binding non-specifically to a cell membrane without
35 disrupting that membrane (e.g. the ricin toxin B chain) when combined with a toxin (e.g. the δ -endotoxins CryIaB and CryIaC) can increase the range of molecular interactions

available to the toxins thereby potentially broadening the spectrum of their activity. In particular the Examples show an increased toxicity compared to the unmodified toxin both *in vitro* (towards Sf21 cells) and *in vivo* (towards the striped stem borer). Additionally, the addition of a novel binding domain is likely to delay or prevent the evolution of resistance in insect populations, as insects are less likely to undergo mutations that abolish two or more distinct cellular uptake activities.

Example 7: Binding of lectins, Bt toxin and Bt-lectin fusions to insect gut polypeptides

Methodology

Briefly, guts were dissected from two insect pests of rice, the striped stem borer used for the insect bioassays described above, and a homopteran species, rice brown planthopper (*Nilaparvata lugens*). Extracted gut polypeptides were separated by SDS-polyacrylamide gel electrophoresis, blotted and probed with lectins, Bt toxin, or Bt-lectin fusion protein; bound probe was then detected by suitable specific antibody.

In more detail, a construct encoding a His-tagged fusion of domain 1 of the Bt toxin CryIAc and snowdrop lectin (GNA) (designated JD1) was first expressed in *E. coli*. The fusion protein was purified by chromatography on Ni-NTA agarose beads (Qiagen) after solubilization, dialysed to remove denaturants, and concentrated by ultrafiltration to give a preparation of soluble, functional protein. The final concentration and purity were estimated by SDS-PAGE. Brown planthopper (*Nilapavata lugens*) midguts were dissected from insects freshly collected from rice plants, and homogenized in SDS sample buffer by sonication. Striped stem borer midguts (provided by Dr. Mike Cohen, IIRI) were collected

from late-instar larvae and were treated similarly. Solubilised gut protein was then separated by SDS-PAGE (12.5% acrylamide) and transferred onto nitrocellulose membranes. The amount of protein loaded was equivalent to 1.5
5 guts per lane for brown planthopper; for striped stem borer, approx. 5 μg of protein was loaded per lane. After incubation in blocking reagent (Sigma) for 60 minutes, membranes containing the gut proteins were probed by incubation with
10 JDI, CrylAc (a gift from Dr. David Ellar; the protoxin was activated by trypsin treatment as described (53), GNA (Drs. W. Peumans and E. van Damme, Catholic University of Leuven, Belgium) or *Ricinus communis* agglutinin (Sigma) respectively. Incubation was carried out for 60 minutes at 25°C, at a concentration of 1 $\mu\text{g ml}^{-1}$. Membranes were washed three times,
15 5 min per wash, with 20 ml Tris-buffered Triton-saline (TBS-T; 50mM Tris-HCl buffer, pH 7.2, containing 0.15 M NaCl and 0.1% Triton X-100). Ligand binding was then detected by incubation with the appropriate primary antibody (anti-CrylAc, a kind gift from Dr. David Ellar; anti-GNA, produced
20 by the authors; anti-*Ricinus communis* agglutinin, Vector Labs) in TBS-T at 1:10,000 dilution of for 60 minutes at 25°C. The membrane was washed again as above and incubated with the secondary antibody (HRP-conjugated; Bio-Rad) at a dilution of 1: 5000. The membrane was washed again as above
25 and further rinsed in distilled water twice before ECL reagents (Amersham Pharmacia Biotech, UK) were added, and the blot was exposed to X-ray film following the manufacturer's instructions.

30 Results

The combination of *Ricinus communis* lectin as a probe and
anti-*Ricinus communis* lectin antibodies as a detection
reagent showed strong binding to a large number of
35 polypeptides in extracts from gut tissues of both insects. In contrast, the CrylAc protein probe only bound strongly to one

polypeptide in the same extracts (approx. 45 kDa in striped stem borer and 90 kDa in brown planthopper). To further characterise differences in binding between Bt toxin and a Bt-lectin fusion, a fusion protein between the specific mannose-binding lectin from snowdrop (*Galanthus nivalis* agglutinin; GNA) and Cry1Ac was produced by expression of a suitable gene construct in *E. coli*. Binding of the fusion protein to insect gut polypeptides was then compared to that of GNA and Cry1Ac proteins separately. In agreement with previous results, GNA bound strongly to polypeptides of about 75 kDa (2 bands) and 50 kDa extracted from rice brown planthopper gut, and bound strongly to a polypeptide of approx. 80 kDa from striped stem borer gut. GNA also bound to a 45-kDa polypeptide in stem borer gut extracts, a similar molecular weight to the major band detected by Cry1Ac. The GNA-Cry1Ac fusion bound only very weakly to the 85-kDa polypeptide recognised by GNA in striped stem borer gut, but bound to the 45-kDa polypeptide recognised by both GNA and Cry1Ac toxin. On the other hand, the fusion showed binding to all the major polypeptides recognised by GNA and by Cry1Ac toxins in brown planthopper gut extracts (approximately 90 kDa, 75 kDa and 45 kDa). These results show that the lectin-Bt fusions have different binding specificities to polypeptides extracted from insect gut tissues, compared to the Bt toxin from which they are derived.

Discussion

In the experiments above, purified lectins, Bt toxins and Bt-lectin fusion proteins were allowed to react with polypeptides extracted from insect guts. The results showed that the galactose-binding domain in ricin binds strongly to many more polypeptides in insect gut extracts than Cry1Ac toxin. The bifunctional nature of the binding of lectin-Bt fusion proteins (i.e. with binding properties which are

derived from both the contributing protein domains) was shown directly by binding assays with a purified GNA-Cry1Ac fusion protein on polypeptides from insect guts.

5 References

1. Monette et al. (1997). Applied and Environmental Microbiology 63 (2), 440-447.
2. Luckow, (1991). Cloning and expression of heterologous
10 genes in insect cells with baculovirus vectors, p.97-151. Prokop et al., (Ed), Recombinant DNA technology and applications. McGraw-Hill, New York, NY.
3. Ferrini et al., (1995) European Journal of Biochemistry 233, 772-777.
- 15 4. Ge et al., (1991). The Journal of Biological Chemistry 266 (27), 17954-17958.
5. Schnepf and Whitley, (1985). The Journal of Biological Chemistry 260, (10), 6273-6280.
6. Dean et al., (1996) Gene 179, 111-117.
- 20 7. Weyer et al., (1990). Journal of General Virology 71, 1525-1534.
8. Martens et al., (1990). Applied and Environmental Microbiology 56 (9), 2764-2770.
9. Merryweather et al., (1990). Journal of General Virology
25 71, 1535-1544.
10. Miller, (1988). Annual Review of Microbiology 42, 177-199.
11. Pang et al., (1992). Journal of General Virology 73, 89-101.
- 30 12. Hofmann et al., (1988). Proc.Natl.Acad.Sci. USA 85, 7844-7844.
13. Vadlamudi et al., (1995). The Journal of Biological Chemistry 270 (10) 5490-5494.
14. Lee et al., (1996). Applied and Environmental
35 Microbiology 62 (8) 2845-2849.

15. Masson et al., (1995). The Journal of Biological Chemistry 270 (35), 20309-20315.
16. Tabashnik et al., (1997). Proc.Natl.Acad.Sci. 94, 1640-1644.
- 5 17. Tabashnik, (1994). Annual Review of Entomology 39, 47-79.
18. Tabashnik et al. Applied and Environmental Microbiology 62 (8) 2839-2844.
19. Perlak et al., (1990). Bio/Technology 8, 939-943.
- 10 20. Vaek et al., (1989). Cell Cult. Somatic Genet. Plants 6, 425-439.
21. Vaek et al., (1987). Nature 327, 33-37.
22. Cornelissen, (1989). Nucleic Acids Research 17, 7203-7209.
- 15 23. Perlak et al., (1991). Proc.Natl.Acad.Sci 88, 3324-3328.
24. Arsine et al., (1995). Plant Molecular Biology 28, 513-524.
25. Murray et al., (1989). Nucleic Acids Research 17, 477-498.
- 20 26. Wolin and Walter, (1988). Embo Journal 7, 3559-3569.
27. Koziel et al., (1993). Bio/Technology 11, 194-199.
28. Dellaporta and Calderon-Urrea, (1994). Science 266, 1501-1505.
- 25 29. Irish, (1996). BioEssays 18 (5), 363-369.
30. Heslop-Harrison, (1961). Proc.Linn.Soc., London. 172, 108-123.
31. Hansen et al., (1976). Crop Science. 16, 371-374.
32. Morino et al., (1995). Biol.Pharm.Bull. 18 (12) 1770-1772.
- 30 33. Endo and Tsurugi, (1987). J.Biol.Chem. 262, 8128.
34. Wales et al., (1992). Archives of Biochemistry and Biophysics 294 (1), 291-296.
35. Wales et al., (1991). The Journal of Biological

- Chemistry 266 (29), 19172-19179.
36. Sardana et al., (1996). Plant Cell Reports 15, 677-681.
 37. GIBCO (1996). BAC-TO-BAC™ baculovirus expression systems: Instruction Manual, 1-33.
 - 5 38. King and Possee, (1990). The baculovirus expression system: A laboratory guide. Chapman and Hall, 143-144.
 39. Molecular probes product information sheet, live/dead viability/cytotoxicity kit (L-3224), ppl._
 40. Glaze and Rye (1992) Nature 359: 859-861.
 - 10 41. Bell et al (1988) J. Orthopaedic Res. 6: 467-474.
 42. Johnson (1994) J. Invertebr. Pathol. 63: 123-129.
 43. [see 1]
 44. Newton et al (1992) J. Biol. Chem. 267: 11917-11922.
 45. Gonatas et al (1975) Exp. Cell Res. 94: 426-431.
 - 15 46. [see 36]
 47. Bradford (1976) Annal. Biochem. 72: 248-254.
 48. Vain et al (1993) Plant Cell Rep. 12: 84-88.
 49. Cooley et al (1995) Theoret. Appl. Genet. 90, 97-104.
 50. Klein et al (1988) Proc. Natl. Acad. Sci. USA. 85: 4305-4309
 - 20 51. Sudhakar et al (1998) Transgenic Res. 7: 289-294
 52. Sambrook et al (1989). Molecular Cloning: A Laboratory Manual. Second edition, Cold Spring Harbour Lab. Press.
 53. Knight et al (1994) Mol. Microbiol. 11: 429-436.

Claims

1 A nucleic acid molecule encoding a pesticidal fusion
polypeptide comprising (i) a toxin domain; and (ii) a
5 heterologous binding domain capable of binding non-
specifically to a cell membrane without disrupting that
membrane.

2 A nucleic acid as claimed in claim 1 wherein the toxin
10 domain is derived from a *Bacillus thuringiensis* cry toxin.

3 A nucleic acid as claimed in claim 2 wherein the
Bacillus thuringiensis cry toxin is CryIA(b) or (c).

15 4 A nucleic acid as claimed in any one of the preceding
claims wherein the binding domain binds carbohydrate.

5 A nucleic acid as claimed in claim 4 wherein the binding
domain has galactose or galactosyl affinity.

20 6 A nucleic acid as claimed in claim 4 or claim 5 wherein
the binding domain is derived from a lectin.

7 A nucleic acid as claimed in claim 6 wherein the lectin
25 is a type two ribosome inactivating protein.

8 A nucleic acid as claimed in claim 7 wherein the binding
domain is derived from the ricin toxin B chain.

30 9 A nucleic acid as claimed in any one of claims 2 to 8
which comprises all or part of Seq ID No 1 (CryIA(b)) or Seq
ID No 2 (CryIA(c)) or a sequence degeneratively equivalent
thereto.

35 10 A nucleic acid as claimed in any one of claims 2 to 9
which comprises all or part of Seq ID No 3 (RTB1), Seq ID No
4 (RTB2) or Seq ID No 5 (RTB3) or a sequence degeneratively

equivalent thereto.

- 11 A nucleic acid as claimed in claims 9 or claim 10 which comprises the CryIA-RTB combination shown in any one of Seq ID No 6 (CryIA(b)-RTB1); Seq ID No 7 (CryIA(b)-RTB2); Seq ID No 8 (CryIA(b)-RTB3); Seq ID No 9 (CryIA(c)-RTB1); Seq ID No 10 (CryIA(c)-RTB2); or Seq ID No 11 (CryIA(c)-RTB3) or a sequence degeneratively equivalent thereto.
- 12 A nucleic acid as claimed in any one of claims 2 to 8 which comprises a nucleotide sequence which is a homologous variant of any of Seq ID Nos 1 to 11.
- 13 A method of producing the nucleic acid of any one of claims 1 to 12, which method comprises the step of combining a nucleic acid encoding a toxin with a nucleic acid encoding a heterologous binding domain, wherein said binding domain is capable of binding non-specifically to a cell membrane without disrupting it.
- 14 A method as claimed in claim 13 wherein the method further comprises the step of modifying the sequence of the toxin or binding domain by way of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid.
- 15 A method as claimed in claim 14 wherein the modification of the sequence causes an alteration in the codon usage of the sequence.
- 16 A recombinant vector comprising a nucleic acid as claimed in any one of claims 1 to 12.
- 17 A vector as claimed in claim 16 wherein the nucleic acid of any one of claims 1 to 12 is operably linked to a promoter.
- 18 A vector as claimed in claim 17 which is an inducible

promoter which is switched on in response to an elicitor or other plant signal which is triggered in response to predation.

5 19 A vector as claimed in any one of claims 16 to 18 which is a baculovirus vector or a vector suitable for use in a plant.

10 20 A method for transforming a host cell which method includes the step of introducing a vector of any one of claims 16 to 19 into the cell and causing or allowing recombination between the vector and the cell genome to introduce the nucleic acid into the genome.

15 21 A host cell containing the nucleic acid of any one of claims 1 to 12 or the vector of any one of claims 16 to 19.

20 22 A host cell transformed with the nucleic acid of any one of claims 1 to 12 or the vector of any one of claims 16 to 19.

23 A host cell as claimed in claim 21 or claim 22 which is a plant cell.

25 24 A host cell as claimed in claim 23 wherein the plant is a monocot plant.

30 25 A host cell as claimed in claim 24 wherein the monocot is maize or rice.

26 A process for producing a transgenic plant, which process comprises the steps of:

35 (a) performing the method of claim 20 to produce a transformed plant cell;
(b) regenerating a plant from said transformed host cell.

27 A plant obtainable by the process of claim 26, which comprises the host cell of any one of claims 23 to 25.

28 A plant which is a clone, selfed or hybrid progeny, or other descendant of the plant of claim 27, and which comprises the host cell of any one of claims 23 to 25.

29 A plant as claimed in claim 27 or claim 28 which is a monocot.

30 A plant as claimed in claim 29 wherein the monocot is maize or rice.

31 A part or propagule of the plant of any one of claims 27 to 30 which comprises the host cell of any one of claims 23 to 25.

32 A method of influencing or affecting the toxicity of a plant to a pest, which method includes the step of causing or allowing expression from a nucleic acid of any one of claims 1 to 12 in the plant.

33 A pesticidal fusion polypeptide encoded by the nucleic acid of any one of claims 1 to 12.

34 A method for producing the polypeptide of claim 33 which method comprises the step of causing expression from a nucleic acid of any one of claims 1 to 12 in a suitable host cell.

35 A composition comprising the polypeptide of claim 33 plus at least one additional component.

36 A commodity which has been treated with the composition of claim 35 such that it has a reduced susceptibility to attack by a pest.

37 A method for controlling pests comprising the use of the polypeptide of claim 33.

38 A method of assessing the toxicity of a polypeptide to a pest species comprising:

- (i) introducing a nucleic acid encoding said polypeptide into a host cell from that species,
- (ii) causing or allowing the nucleic acid to be expressed in a host cell from that species,
- (iii) observing the viability of the cell and correlating the results of the observation with the toxicity of the polypeptide, wherein the viability is determined by assessing esterase activity or membrane integrity.

39 A method as claimed in claim 37 or claim 38 wherein the pest is a species of insect.

40 A method as claimed in claim 39 wherein the species is selected from *Lepidoptera*, *Coleoptera*, *Culicidae*, *Simuliidae*, *Hymenoptera*, *Homoptera*, *Orthoptera* and *Diptera*.

41 An oligonucleotide selected from the group consisting of:

- LF1=5' CAACAACAAAGGAATTCATGCTGATG 3',
- LB1=5' GGACACACACACTGCAAGCTTGTAAATC 3',
- LB2=5' CGGATCCGAAAGCTTCACATCTAACAC 3', or
- LB3=5' GCTTGCAAGCTTAGACCATATAGCCC 3'.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷: C12N 15/62, C07K 14/32, 14/415, A01N 63/00, C12N 15/10, 15/63, 15/866, 5/14, C12P 21/00, C12Q 1/00	A2	(11) International Publication Number: WO 00/66755 (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/GB00/01633 (22) International Filing Date: 27 April 2000 (27.04.00) (30) Priority Data: 9909796.6 28 April 1999 (28.04.99) GB (71) Applicant (for all designated States except US): PLANT BIOSCIENCE LIMITED [GB/GB]; Norwich Research Park, Colney Lane, Norwich, Norfolk NR4 7UH (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): <u>CHRISTOU</u> , Paul [US/GB]; 38 Glenalmond, Norwich NR4 6AG (GB). MEHLO, Luke [ZW/ZW]; <u>SIRDC</u> , Box 6640, Harare (ZW). (74) Agents: KREMER, Simon, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: PESTICIDAL FUSIONS		
(57) Abstract Disclosed are nucleic acid molecules encoding a pesticidal fusion polypeptide comprising (i) a toxin domain; and (ii) a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting that membrane. Preferably the toxin domain is derived from a <i>Bacillus thuringiensis</i> cry toxin (e.g. CryIA(b) or (c)) and the binding domain is derived from a lectin (e.g. ricin toxin B chain). The use of such fusions may help to inhibit the acquisition of resistance in a pest population treated with the polypeptide. Also disclosed are method and materials for producing and using the nucleic acids and polypeptides encoded thereby. Also vectors (e.g. baculovirus vectors or a vectors suitable for us in a plant), host cells, and plants etc. A further aspect of the invention is a method of assessing the toxicity of a polypeptide to a pest species comprising: (i) introducing a nucleic acid encoding said polypeptide into a host cell from that species, (ii) causing or allowing the nucleic acid to be expressed in a host cell from that species, (iii) observing the viability of the cell and correlating the results of the observation with the toxicity of the polypeptide, wherein the viability is determined by assessing esterase activity or membrane integrity.		

Fig. 1




Fig. 2




Fig. 3a

Nucleotide sequence of CryIA(b) in pFASTBAC1

```

1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATTCCG GATTATTCAT ACCGTCCAC CATCGGGCGC GGATCCATGG
101 ACAACAACCC AACATCAAC GAATGCATTC CATACAAC TGTTGAGTAAC
151 CCAGAAGTTG AAGTACTTGG TGGAGAACGC ATTGAAACCG GTTACACTCC
201 CATCGACATC TCCTTGTCCT TGACACAGTT TCTGCTCAGC GAGTTCGTGC
251 CAGGTGCTGG GTTCGTCTC GGAAGTAGT ACATCATCTG GGGTATCTTT
301 GGTCCATCTC AATGGGATGC ATTCTGGTG CAAATTGAGC AGTTGATCAA
351 CCAGAGGATC GAAGAGTTGC CCAGGAACCA GGCCATCTCT AGGTGGAAG
401 GATTGAGCAA TCTCTACCAA ATCTATGCAG AGAGCTTCAG AGAGTGGGAA
451 GCCGATCCTA CTAACCCAGC TCTCCGCGAG GAAATGCGTA TTCAATTCAA
501 CGACATGAAC AGCGCCTTGA CCACAGCTAT CCCATTGTTT GCAGTCCAGA
551 ACTACCAAGT TCCTCTCTTG TCCGTGTAGG TTCAAGCAGC TAATCTTCAC
601 CTCAGCGTGC TTCGAGACGT TAGCGTGTTC GGGCAAAGGT GGGGATTGCA
651 TGCTGCAACC ATCAATAGCC GTTACAACGA CCTTACTAGG CTGATTGGAA
701 ACTACACCGA CCACGCTGTT CGTTGTGACA AACTGGGCTT GGAGCGTGTC
751 TGGGGTCTCG ATTCTAGAGA TTGGATTAGA TACAACCAAGT TCAGGAGAGA
801 ATTGACCCTC ACAGTTTGG ACATTGTGTC TCTCTTCCCG AACTATGACT
851 CCAGAACCTA CCCTATCCGT ACAGTGTCCC AACTTACCAG AGAAATCTAT
901 ACTAACCCAG TTCTTGAGAA CTCGACGGT AGCTTCCGTG GTTCTGCCCA
951 AGGTATCGAA GGCTCCATCA GGAGCCCA CAATTGATGAC ATCTTGAACA
1001 GCATAACTAT CTACCCGAT GCTCACAGAG GAGAGTATTA CTGCTCTGGA
1051 CACCAGATCA TGGCCTCTCC AGTTGGATTC AGCGGGCCCG AGTTTACCTT
1101 TCCTCTCTAT GGAACATATG GAAACGCCGC TCCACAACAA CGTATCGTTG
1151 CTCAACTAGG TCAGGGTGTC TACAGAACCT TGCTCTCCAC CTGTACAGA
1201 AGACCCCTCA ATATCGGTAT CAACAACCA CAACCTTCCG TTCTTGACGG
1251 AACAGAGTTC GCCTATGGAA CCTCTCTTAA CTTCGCATCC GCTGTTTACA
1301 GAAAGAGCGG AACCGTTGAT TCCTTGGACG AAATCCCACC ACAGAACCAAC
1351 AATGTGCCAC CCAGGCAAGG ATTCTCCAC AGGTGAGCC ACGTGTCCAT
1401 GTTCCGTTCC GGATTACGA ACGTTCCGT GAGCATCATC AGAGCTCTTA

```

Fig. 3a (Cont ...)

1451 TGTTCTCATG GATTCATCGT AGTGCTGAGT TCAACAATAT CATTCCTTCC
1501 TCTCAAATCA CCCAAATCCC ATTGACCAAG TCTACTAACC TTGGATCTGG
1551 AACTTCTGTC GTGAAAGGAC CAGGCTTCAC AGGAGGTGAT ATTCCTAGAA
1601 GAACTTCTCC TGGCCAGATT AGCACCTCA GAGTTAACAT CACTGCACCA
1651 CTTTCTCAAA GATATCGTGT CAGGATTCGT TACGCATCTA CCACTAACTT
1701 GCAATTCCAC ACCTCCATCG ACGGAAGGCC TATCAATCAG GGTAACTTCT
1751 CCGCAACCAT GTCAAGCGGC AGCAACTTGC AATCCGGCAG CTTCAGAACC
1801 GTCGGITTCA CTACTCCTTT CAACTTCTCT AACGGATCAA GCGTTTTCAC
1851 CCTTAGCGCT CATGTGTTCA ATTCTGGCAA TGAAGGTGAC ATTGACCGTA
1901 TTGAGTTTGT GCCTGCCGAA GTTACCTTCG AGGCTGAGTA CTGAGAATTC
1951 AAAGGCCTAC GTCGACGAGC TCACTAGTCG CGGCCGCTTT CGAATCTAGA
2001 GCCTGCAGTC TCGAGGCATG CGGTACCAAG CTTGTCGAGA AGTACTAGAG
2051 GATCATAATC AG

Fig. 3b

Nucleotide sequence of CryIA(c) in pFASTBAC1 Seq ID No 2

```

1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATTCGG GATTATTCAT ACGTCCCAC CATCGGGCGC GGATCCATGG
101  ACAACAACCC AAACATCAAC GAATGCATTC CATACAAC TGAGTAAC
151  CCAGAAGTTG AAGTACTTGG TGGAGAACGC ATTGAAACCG GTTACACTCC
201  CATCGACATC TCCTTGTCCT TGACACAGTT TCTGCTCAGC GAGTTCGTGC
251  CAGGTGCTGG GTTCGTTCTC GGACTAGTTG ACATCATCTG GGGTATCTTT
301  GGTCATCTC AATGGGATGC ATTCCTGGTG CAAATTGAGC AGTTGATCAA
351  CCAGAGGATC GAAGAGTTCC CCAGGAACCA GGCCATCTCT AGGTTGAAG
401  GATTGAGCAA TCTCTACCAA ATCTATGCAG AGAGCTTCAG AGAGTGGAA
451  GCGATCCTA CTAACCCAGC TCTCCGCGAG GAAATGCGTA TTCAATTCAA
501  CGACATGAAC AGCGCCITGA CCACAGCTAT CCCATTGTTT GCATTCGAGA
551  ACTACCAAGT TCCTCTCTTG TCGGTGTACG TTCAAGCAGC TAATCTTCAC
601  CTCAGCGTGC TTCGAGACGT TAGCGTGTTT GGGCAAAGGT GGGGATCGA
651  TGCTGCAACC ATCAATAGCC GTTACAACGA CCTTACTAGG CTGATTGGAA
701  ACTACACCGA CCACGCTGTT CGTTGGTACA ACACTGCGCTT GGAGCGTGTC
751  TGGGGTCTTG ATTCTAGAGA TTGGATTAGA TACAACCACT TCAGGAGAGA
801  ATTGACCCTC ACAGTTTGGT ACATTGTGTC TCTCTTCCCG AACTATGACT
851  CCAGAACCTA CCTATCCGT ACAGTGTCCT AACCTACCG AGAAATCTAT
901  ACTAACCCAG TTCTTGAGAA CTTGACGCT AGCTTCCGTG GTTCTGCCCA
951  AGGTATCGAA GGCTCCATCA GGAGCCCACT CTTGATGGAC ATCTTGAACA
1001 GCATAACTAT CTACACCGAT GCTCACAGAG GAGAGTATTA CTGCTCTGGA
1051 CACCAGATCA TGGCCTCTCC AGTTGSAATC AGCGGGCCCG AGTTTACCTT
1101 TCCTCTCTAT GGAACATAGG GAAACGCCGC TCCACAACAA CGTATCGTTG
1151 CTCAACTAGG TCAGGGGTGC TACAGAACCT TGTCCTCCAC CTTGTACAGA
1201 AGACCCCTCA ATATCGGTAT CAACAACCG CAACTTCCG TTCTTGACGG
1251 AACAGAGTTC GCCTATGGAA CCTCTTCTAA CTTGCCATCC GCTGTTTACA
1301 GAAAGAGCGG AACCGTTGAT TCCTTGGAGC AAATCCCACC ACAGAACAAC
1351 AATGTGCCAC CCAGGCAAGG ATTCCTCCAC AGGTTGAGCC ACGTGTCCAT
1401 GTTCCGTTCG GGATTACGCA ACAGTTCGTG GAGCATCATC AGAGTCTCTA

```


Fig. 3b (Cont ...)

1451 TGTTCCTCTTG GATACACCGT AGTGCTGAGT TCAACAACAT CATCGCATCC
1501 GATAGTATTA CTCAAATCCC TGCAGTGAAG GGAAACTTTC TCTTCAACGG
1551 TTCTGTCAATT TCAGGACCAG GATTCACTGG TGGAGACCTC GTTAGACTCA
1601 ACAGCAGTGG AAATAACATT CAGAATAGAG GGTATATTGA AGTTCCAATT
1651 CACTTCCCAT CCACATCTAC CAGATATAGA GTTCGTGTGA GGTATGCTTC
1701 TGTGACCCCT ATTCACTCA ACGTTAATTG GGGTAATTCA TCCATCTTCT
1751 CCAATACAGT TCCAGCTACA GCTACCTCCT TGGATAATCT CCAATCCAGC
1801 GATTTGCGTT ACTTTGAAAG TGCCAATGCT TTTACATCTT CACTCGGTAA
1851 CATCGTGGGT GTTAGAAACT TTAGTGGGAC TGCAGGAGTG ATTATCGACA
1901 GATTCGAGTT CATTCCAGTT ACTGCAACAC TCGAGGCTGA ATGAGAATTC
1951 AAAGGCCCTAC GTCGACGAGC TCACTAGTCG CGGCCGCTTT CGAATCTAGA
2001 GCCTGCAGTC TCGAGGCATG CGGTACCAAG CTTGTCGAGA AGTACTAGAG
2051 GATCATAATC AG

Fig. 3c

Nucleotide sequence of RTB1 in pFASTBAC1 Seq ID No 3

```
1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATTTCCG GATTATTCAT ACCGTCCCAC CATCGGGCGC GGATCCCGGT
101 CCGAAGCGCG CGGAATTCAT GCTGATGTTT GTATGGATCC TGAGCCCAT
151 GTGCGTATCG TAGGTCGAAA TGGTCTATGT GTTGATGTTA GGGATGGAAG
201 ATTCCACAAC GGAAACGCAA TACAGTTGTG GCCATGCAAG TCTAATACAG
251 ATGCAAAATCA GCTCTGGACT TTGAAAAGAG ACAATACTAT TCGATCTAAT
301 GGAAAGTGTT TAACTACTTA CGGGTACAGT CCGGGAGTCT ATGTGATGAT
351 CTATGATTGC AATACTGCTG CAACTGATGC CACCCGCTGG CAAATATGGG
401 ATAATGGAAC CATCATAAAT CCCAGATCTA GTCTAGTTTT AGCAGCGACA
451 TCAGGGAACA GTGGTACCAC ACTTACGGTG CAAACCAACA TTTATGCCGT
501 TAGTCAAGGT TGGCTTCCTA CTAATAATAC ACAACCTTTT GTTACAACCA
551 TTGTTGGGCT ATATGGTCTG TGCTTGCAAG CAAATAGTGG ACAAGTATGG
601 ATAGAGGACT GTAGCAGTGA AAAGGCTGAA CAACAGTGGG CTCITTTATGC
651 AGATGGTTCA ATACGTCCTC AGCAAAACCG AGATAATTGC CTTACAAGTG
701 ATTCTAATAT ACGGGAAACA GTTGTTAAGA TCCTCTCTTG TGGCCCTGCA
751 TCCTCTGGCC AACGATGGAT GTTCAAGAAT GATGGAACCA TTTTAAATTT
801 GTATAGTGGA TTGGTGTTAG ATGTGAGGCG ATCGGATCCG AGCCTTAAC
851 AAATCATTCT TTACCCCTCTC CATGGTGACC CAAACCAAT ATGGTTACCA
901 TTATTTTGAT AGACAGATTA CAAGCTTGTC GAGAAGTACT AGAGGATCAT
951 AATCAG
```

Fig. 3d

Nucleotide sequence of RTB2 in pFASTBAC1

Seq ID No 4

```
1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATTCCG GATTATTCAT ACCGTCCCAC CATCGGGCGC GGATCCCGGT
101 CCGAAGCGCG CGGAATTCAT GCTGATGTTT GTATGGATCC TGAGCCCATA
151 GTGCGTATCG TAGGTCGAAA TGGTCTATGT GTTGATGTTA GGGATGGAAG
201 ATTCCACAAC GGAACGCAA TACAGTTGTG GCCATGCAAG TCTAATACAG
251 ATGCAAATCA GCTCTGGACT TTGAAAAGAG ACAATACTAT TCGATCTAAT
301 GGAAGTGTT TAACTACTTA CGGGTACAGT CCGGGAGTCT ATGTGATGAT
351 CTATGATTGC AATACTGCTG CAACTGATGC CACCCGCTGG CAAATATGGG
401 ATAATGGAAC CATCATAAAT CCCAGATCTA GTCTAGTTTT AGCAGCGACA
451 TCAGGGAACA GTSGTACCAC ACTTACGGTG CAAACCAACA TTTATGCCGT
501 TAGTCAAGGT TGGCTTCCTA CTAATAATAC ACAACCTTTT GTTACAACCA
551 TTGTTGGGCT ATATGGTCTG TGCTTGCAAG CAAATAGTGG ACAAGTATGG
601 ATAGAGGACT GTAGCAGTGA AAAGGCTGAA CAACAGTGGG CTCCTTTATGC
651 AGATGGTTCA ATACGTCTC AGCAAAACCG AGATAATTGC CTTACAAGTG
701 ATTCTAATAT ACGGGAAACA GTTGTTAAGA TCCTCTCTTG TGGCCCTGCA
751 TCCTCTGCC AACGATGGAT GTTCAAGAAT GATGGAACCA TTTTAAATT
801 GTATAGTGA TTGGTGTTAG ATGTGAAGCT TGTCGAGAAG TACTAGAGGA
851 TCATAATCAG
```

Fig. 3e

Nucleotide sequence of RTB3 in pFASTBAC1. Seq ID No 5

```
1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATTCCG GATTATTCAT ACCGTCCCAC CATCGGGCGC GGATCCCGGT
101 CCGAAGCGCG CGGAATTCAT GCTGATGTTT GTATGGATCC TGAGCCCATA
151 GTGCGTATCG TAGGTCGAAA TGGTCTATGT GTTGATGTTA GGGATGGAAG
201 ATTCCACAAC GGAAACGCAA TACAGTTGTG GCCATGCAAG TCTAATACAG
251 ATGCAAATCA GCTCTGGACT TTGAAAAGAG ACAATACTAT TCGATCTAAT
301 GGAAAGTGTT TAACTACTTA CGGGTACAGT CCGGGAGTCT ATGTGATGAT
351 CTATGATTGC AATACTGCTG CAACTGATGC CACCCGCTGG CAAATATGGG
401 ATAATGGAAC CATCATAAAT CCCAGATCTA GTCTAGTTTT AGCAGCGACA
451 TCAGGGAACA GTGGTACCAC ACTTACGCTG CAAACCAACA TTTATGCCGT
501 TAGTCAAGGT TGGCTTCCTA CTAATAATAC ACAACCTTTT GTTACAACCA
551 TIGTTGGGCT ATATGGTCTA AGCTTGTCGA GAAGTACTAG AGGATCATAA
601 TCAG
```

Fig. 3f

Nucleotide sequence of CryIA(b)-RTB1 in pFASTBAC1 Seq ID No 6

```
1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACTAT
51  AAATATTCCG GATTATTCAT ACCGTCCAC CATCGGGCGC GGATCCATGG
101 ACACAACCCC AACATCAAC GAATGCATTC CATACAAC TGAGTAAC
151 CCAGAAGTTG AAGTACTTGG TGGAGAACGC ATTGAAACCG GITACACTCC
201 CATCGACATC TCCTTGTCCT TGACACAGTT TCTGCTCAGC GAGTTCGTGC
251 CAGGTGCTGG GTTCGTTCTC GGACTAGTTG ACATCATCTG GGGTATCTTT
301 GGTCCATCTC AATGGGATGC ATTCCTGGTG CAAATTGAGC AGTTGATCAA
351 CCAGAGGATC GAAGAGTTCG CCAGGAACCA GGCCATCTCT AGGTTGGAAG
401 GATTGAGCAA TCTCTACCAA ATCTATGCAG AGAGCTTCAG AGAGTGGGAA
451 GCCGATCCTA CTAACCCAGC TCTCCGCGAG GAAATGCGTA TTCAATTCAA
501 CGACATGAAC AGCGCCTTGA CCACAGCTAT CCCATTGTTT GCAGTCCAGA
551 ACTACCAAGT TCCTCTCTTG TCCGTGTACG TTCAAGCAGC TAATCTTCAC
601 CTCAGCGTGC TTCGAGACGT TAGCGTGT TTGGCAAAGGT GGGGATTTCGA
651 TGCTGCAACC ATCAATAGCC GTTACAACGA CCTTACTAGG CTGATTGGAA
701 ACTACACCGA CCACGCTGTT CGTTGGTACA AACTTGCTT GGAGCGTGTC
751 TGGGGTCTCT ATTCTAGAGA TTGGATTAGA TACAACCACT TCAGGAGAGA
801 ATTGACCCTC ACAGTTTGG ACATTGTGTC TCTCTTCCCG AACTATGACT
851 CCAGAACCTA CCCTATCCGT ACAGTGTCCC AACTTACCAG AGAAATCTAT
901 ACTAACCCAG TTCTTGAGAA CTTGACGCT AGCTTCCGTG GTTCTGCCCA
951 AGGTATCGAA GGCTCCATCA GGAGCCCACA CTGATGGAC ATCTTGAACA
1001 GCATAACTAT CTACACCGAT GCTCACAGAG GAGAGTATTA CTGGTCTGGA
1051 CACCAGATCA TGGCCTCTCC AGTTGGATTG AGCGGGCCCG AGTTTACCTT
1101 TCCTCTCTAT GGAAGTATGG GAAACGCCGC TCCACAACAA CGTATCGTTG
1151 CTCAACTAGG TCAGGTGTC TACAGAACCT TGTCTTCCAC CTTGTACAGA
```

Fig 3f (Cont ...)

1201 AGACCCCTTCA ATATCGGTAT CAACAACCAG CAACCTTCCG TTCTTGACGG
1251 AACAGAGTTC GCCTATGGAA CCTCTTCTAA CTGECATCC GCTGTTTACA
1301 GAAAGAGCGG AACCGTTGAT TCCTTGGACG AAATCCCAAC ACAGAACAAAC
1351 AATGTGCCAC CCAGGCAAGG ATTCTCCAC AGGTTGAGCC ACGTGCCAT
1401 GTTCCGTTCC GGATTCAGCA ACAGTTCCGT GAGCATCATC AGAGCTCCTA
1451 TGTCTCATG GATTTCATCGT AGTGCTGAGT TCAACAATAT CATTCTTCC
1501 TCTCAAATCA CCCAAATCCC ATTGACCAAG TCTACTAACC TTGGATCTGG
1551 AACTTCTGTC GTGAAAGGAC CAGGCTTCA AGGAGGTGAT ATTCTTAGAA
1601 GAACCTCTCC TGGCCAGATT AGCACCTCA GAGTTAACAT CACTGCACCA
1651 CTTTCTCAA GATATCGTGT CAGGATTGCT TACGCATCTA CCACTAACTT
1701 GCAATTCCAC ACCTCCATCG ACGGAAGGCC TATCAATCAG GGTAACTTCT
1751 CCGCAACCAT GTCAAGCGGC AGCAACTTGC AATCCGGCAG CTCAGAAACC
1801 GTCGGTTTCA CTACTCCTTT CAACCTTCTT AACGGATCAA GCGTTTTCAC
1851 CCTTAGCGCT CATGTGTICA ATCTTGCGAA TGAAGTGAT ATTGACCGTA
1901 TTGAGTTTGT GCCTGCCGAA GTTACCTTCG AGGCTGAGTA CTGAGAATTC
1951 ATGCTGATGT TTGTATGGAT CCTGAGCCCA TAGTGGGTAT CGTAGGTGCA
2001 AATGGTCTAT GTGTTGATGT TAGGGATGGA AGATTCCACA ACGGAAACGC
2051 AATACAGTTG TGGCCATGCA AGTCTAATAC AGATGCCAAAT CAGCTCTGGA
2101 CTTTGAAAAG AGACAATACT ATTCGATCTA ATGGAAGTG TTTAACTACT
2151 TACGGGTACA GTCCGGGAGT CTATGTGATG ATCTATGATT GCAATACTGC
2201 TGCAACTGAT GCCACCGCT GGCAAATATG GGATAATGGA ACCATCATAA
2251 ATCCCAGATC TAGCTAGTT TTAGCAGCGA CATCAGGSA CAGTGGTACC
2301 ACACCTACGG TGCAAACCAA CATTATATGCC GTTAGTCAAG GTTGGCTTCC
2351 TACTAATAAT ACACAACCTT TTGTTACAAC CATTGTTGGG CTATATGCTC
2401 TGTGCTTGCA AGCAAAATAGT GGACAAGTAT GGATAGAGGA CTGTAGCAGT
2451 GAAAAGGCTG AACCAACAGT GGCCTTTTAT GCAGATGGTT CAATACGTCC
2501 TCAGCAAAAC CGAGATAATT GCCTTACAAG TGATTCTAAT ATACGGGAAA
2551 CAGTTGTTAA GATCCTCTCT TGTGGCCCTG CATCCTCTGG CCAACGATGG
2601 ATGTTCAAGA ATGATGGAAC CATTTTAAAT TTGTATAGTG GATTGGTGT
2651 AGATGTGAGG CGATCGGATC CGAGCCTTAA ACAAAATCAT CTTTACCCTC
2701 TCCATGGTGA CCCAAACCAA ATATGGTTAC CATTATTTTG ATAGACAGAT
2751 TACAAGCTTG TCGAGAAGTA CTAGAGGATC ATAATCAG

Fig. 3g

Nucleotide sequence of CryIA(b)-RTB2 in pFASTBAC1 : Seq ID No 7

```
1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATCCCG GATTATTTCAT ACCGTCCAC CATCGGGCGC GGATCCCATGG
101  ACAACAACCC AACATCAAC GAATGCATTC CATACAACCTG CTTGAGTAAC
151  CCAGAAAGTTG AAGTACTTGG TGGAGAACGC ATTGAAACCG GTTACACTCC
201  CATCGACATC TCCTTGTCCT TGACACAGTT TCTGCTCAGC GAGTTCGTGC
251  CAGGTGCTGG GTTCGTTCTC GGACTAGTTG ACATCATCTG GGSTATCTTT
301  GGTCCATCTC AATGGGATGC ATTCTGTGTG CAAATTGAGC AGTTGATCAA
351  CCAGAGGATC GAAGAGTTCC CCAGGAACCA GGCCATCTCT AGGTTGGAAG
401  GATTGAGCAA TCTCTACCAA ATCTATGCAG AGAGCTTCAG AGAGTGGGAA
451  CGCGATCCTA CTAACCCAGC TCTCCGCGAG GAAATGCGTA TTCAATTCAA
501  CGACATGAAC AGCGCCTTGA CCACAGCTAT CCCATTGTTC GCAGTCCAGA
551  ACTACCAAGT TCCTCTCTTG TCCGTGTACG TTCAAGCAGC TAATCTTCAC
601  CTCAGCGTGC TTCGAGACGT TAGCGTGTTC GGGCAAAGGT GGGGATTGGA
651  TGCTGCAACC ATCAATAGCC GTTACAACGA CCTTACTAGG CTGATTGGAA
701  ACTACACCGA CCACGCTGTT CGTTGGTACA ACACTGGCTT GGAGCGTGTC
751  TGGGGTCTCT ATTCTAGAGA TTGGATTAGA TACAACCACT TCAGGAGAGA
801  ATTGACCCCTC ACAGTTTGG ACATTGTGTC TCTCTCCCG AACTATGACT
851  CCAGAACCTA CCCTATCCGT ACAGTGTCCT AACTTACCAG AGAAATCTAT
901  ACTAACCCAG TTCTTGAGAA CTTCGACGGT AGCTTCCGTG GTTCTGCCCA
951  AGGTATCGAA GGCTCCATCA GGAGCCACA CTGATGGAC ATCTTGAACA
1001  GCATAACTAT CTACACCGAT GCTCACAGAG GAGAGTATTA CTGGCTCGGA
1051  CACCAGATCA TGGCCTCTCC AGTTGGATTC AGCGGGCCCG AGTTTACCTT
1101  TCCTCTCTAT GAAACTATGG GAAACGCCGC TCCACAACAA CGTATCGTTG
1151  CTCAACTAGG TCAGGGTGTC TACAGAACCT TGTCTTCCAC CTGTGTACAGA
```

Fig. 3g (Cont ...)

1201 AGACCCCTTCA ATATCGGTAT CAACAACCAG CAACCTTCCG TTCTTGACGG
 1251 AACAGAGTTC GCCTATGGAA CCTCTTCTAA CTTGCCATCC GCTGTTTACA
 1301 GAAAGAGCGG AACCGTTGAT TCCTTGGACG AAATCCCACC ACAGAACAAAC
 1351 AATGTGCCAC CCAGGCAAGG ATTCTCCCAC AGGTTGAGCC ACGTTGCCAT
 1401 GTTCCGTTCC GGATTGAGCA ACAGTTCCGT GAGCATCATC AGAGCTCCTA
 1451 TGTTCCTCATG GATTTCATCGT AGTGCTGAGT TCAACAATAT CATTCTCTCC
 1501 TCTCAATCA CCCAATCCC ATTGACCAAG TCTACTAACC TTGGATCTGG
 1551 AACTTCTGTC GTGAAAGGAC CAGGCTTCAC AGGAGTGAT ATTCTTAGAA
 1601 GAACTTCTCC TGGCCAGATT AGCACCCCTA GAGTTAACAT CACTGACCA
 1651 CTTTCTCAAA GATATCGTGT CAGGATTCGT TACGCATCTA CCACTAACTT
 1701 GCAATTCAC ACCTCCATCG ACGGAAGGCC TATCAATCAG GGTAACTTCT
 1751 CCGCAACCAT GTCAAGCGGC AGCAACTTGC AATCCGGCAG CTTCAGAAAC
 1801 GTCGGTTTCA CTACTCCTTI CAACTTCTCT AACGGATCAA GCGTTTTCAC
 1851 CCTTAGCGCT CATGTGTTCA ATTCTGGCAA TGAAGTGATC ATTGACCGTA
 1901 TTGAGTTTGT GCCTGCCGAA GTTACCTTCG AGGCTGAGTA CTGAGAATTC
 1951 ATGCTGATGT TTGTATGGAT CCTGAGCCCA TAGTGCGTAT CGTAGGTCGA
 2001 AATGCTCTAT GTGTTGATGT TAGGGATGGA AGATTCCACA ACGGAAACGC
 2051 AATACAGTTG TGGCCATGCA AGTCTAATAC AGATGCAAAAT CAGCTCTGGA
 2101 CTTTGAAAAG AGACAATACT ATTCGATCTA ATGGAAAGTG TTTAACTACT
 2151 TACGGGTACA GTCCGGGAGT CTATGTGATG ATCTATGATT GCAATACTGC
 2201 TGCAACTGAT GCCACCCGCT GGCAATATG GGATAATGGA ACCATCATAA
 2251 ATCCCAGATC TAGTCTAGTT TTAGCAGCGA CATCAGGGAA CAGTGGTACC
 2301 ACACTTACGG TGCAAAACCA CATTATGCC GTTAGTCAAG GTTGCCCTCC
 2351 TACTAATAAT ACACAACCTT TTGTTACAAC CATTGTTGGG CTATATGGTC
 2401 TGTGCTTGCA AGCAAAAGT GGACAAGTAT GGATAGAGGA CTGTAGCAGT
 2451 GAAAAGGCTG AACAACAGTG GGCTCTTTAT GCAGATGGETT CAATACGTCC
 2501 TCAGCAAAAC CGAGATAATT GCCTTACAAG TGATTCTAAT ATACGGGAAA
 2551 CAGTTGTTAA GATCCTCTCT TGTGGCCCTG CATCCTCTGG CCAACGATGG
 2601 ATGTTCAAGA ATGATGGAAC CATTTTAAAT TTGTATAGTG GATTGGTGTT
 2651 AGATGTGAAG CTTGTCGAGA AGTACTAGAG GATCATAATC AG

Fig. 3h

Nucleotide sequence of CryIA(b)-RTB3 in pFASTBAC1 : Seq ID No 8

```
1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATTCCG GATTATTTCAT ACCGTCCCAC CATCGGGCGC GGATCCATGG
101  ACAACAACCC AAACATCAAC GAATGCATTC CATACAACCTG CTTGAGTAAC
151  CCAGAAGTTG AAGTACTTGG TGGAGAAGCG ATTGAAACCG GTTACACTCC
201  CATGACATC TCCTTGTCCT TGACACAGTT TCTGCTCAGC GAGTTCGTGC
251  CAGGTGCTGG GTTCGTTCTC GGAAGTAGTT ACATCATCTG GGGTATCTTT
301  GGTCCATCTC AATGGGATGC ATTCCTGGTG CAAATTGAGC AGTTGATCAA
351  CCAGAGGATC GAAGAGTTCC CCAGGAACCA GGCCATCTCT AGGTGGAAG
401  GATTAGSCAA TCTCTACCAA ATCTATGCAG AGAGCTTCAG AGAGTGGAA
451  GCCGATCCTA CTAACCCAGC TCTCCGCGAG GAAATGCGTA TTCAATTCAA
501  CGACATGAAC AGCGCCTTGA CCACAGCTAT CCCATTGTTT GCAGTCCAGA
551  ACTACCAAGT TCCTCTCTTG TCCGTGTACG TTCAAGCAGC TAATCTTCAC
601  CTCAGCGTGC TTCGAGACGT TAGCGTGTTC GGGCAAAGGT GGGGATTGGA
651  TGCTGCACCC ATCAATAGCC GTTACAACGA CTTACTAGG CTTGATTGAA
701  ACTACACCGA CCACGCTGTT CGTTGGTACA ACACTGGCTT GGAGCGTGTC
751  TGGGGTCTTG ATTCTAGAGA TTGGATTAGA TACAACCACT TCAGGAGAGA
801  ATTGACCCCT ACAGTTTGG ACATTGTGTC TCTCTTCCCG AACTATGACT
851  CCAGAACCTA CCCTATCCGT ACAGTGTCCC AACTTACCAG AGAAATCTAT
901  ACTAACCCAG TTCTTGAGAA CTTGACGGT AGCTTCCGTG GTTCTGCCCA
951  AGGTATCGAA GGCTCCATCA GGAGCCACCA CTTGATGGAC ATCTTGAACA
1001  GCATAACTAT CTACACCGAT GCTCACAGAG GAGAGTATTA CTGGTCTGGA
1051  CACCAGATCA TGGCCTCTCC AGTTGGATTC AGCGGGCCCG AGTTTACCTT
1101  TCCTCTCTAT GGAACATAGG GAAACGCCGC TCCACAACAA CGTATCGTTG
1151  CTCAACTAGG TCAGGGTGTC TACAGAACCT TGTCTTCCAC CTTGTACAGA
```

Fig. 3n (Cont ...)

1201 AGACCCCTTCA ATATCGGTAT CAACAACCAG CAACTTTCGG TTCTTGACGG
1251 AACAGAGTTC GCCTATGGAA CCTCTCTAA CTGCCATCC GCTGTTTACA
1301 GAAAGAGCGG AACCGTTGAT TCCTTGSACG AAATCCCACC ACAGAACAAC
1351 AATGTGCCAC CCAGGCAAGG ATTCTCCAC AGGTGAGCC ACGTGTCCAT
1401 GTTCCGTTCC GGATTCAGCA ACAGTTCGGT GAGCATCATC AGAGCTCCTA
1451 TGTCTCATG GATTTCATGT AGTGCTGAGT TCAACAATAT CATTCCTTCC
1501 TCTCAAATCA CCCAAATCCC ATTGACCAAG TCTACTAACC TTGGATCTGG
1551 AACTTCTGTC GTGAAAGGAC CAGGCTTAC AGGAGGTGAT ATTCITAGAA
1601 GAACTTCTCC TGCCAGATG AGCACCCTCA GAGTTAATC CACTGCACCA
1651 CTTTCTCAAA GATATCGTGT CAGGATTCGT TACGCATCTA CCACTAACTT
1701 GCAATTCAC ACCTCCATCG ACGGAAGGCC TATCAATCAG GGTAACTTCT
1751 CCGCAACCAT GTCAAGCGG AGCAACTTGC AATCCGGCAG CTTCAGAACC
1801 GTCGGTTTCA CTAATCCTTT CAACTTCTCT AACGGATCAA GCGTTTTCAC
1851 CCTTAGCGCT CATGTGTTCA ATTCTGGCAA TGAAGTGTA ATTGACCGTA
1901 TTGAGTTTGT GCCTGCCGAA GTTACCTTCG AGGCTGAGTA CTGAGAACTC
1951 ATGCTGATGT TTGTATGGAT CCTGAGCCCA TAGTGCCTAT CGTAGGTCGA
2001 AATGCTCTAT GTGTTGATGT TAGGGATGGA AGATTCCACA ACGGAACGC
2051 AATACAGTTG TGGCCATGCA AGTCTAATAC AGATGCAAAAT CAGCTCTGGA
2101 CTTTGAAAAG AGACAATACT ATTCGATCTA ATGGAAAGTG TTAACTACT
2151 TACGGGTACA GTCCGGAGT CTATGTGATG ATCTATGATT GCAATACTGC
2201 TGCAACTGAT GCCACCGCT GCCAAATATG GGATAATGGA ACCATCATAA
2251 ATCCAGATC TAGTCTAGTT TTAGCAGCGA CATCAGGSA CAGTGGTACC
2301 ACACTTACGG TGCAAAACCA CATTATGCC GTTAGTCAAG GTTGGCTTCC
2351 TACTAATAAT ACACAACCTT TTGTTACAAC CATTGTTGGG CTATATGGTC
2401 TAAGCTTGTC GAGAAGTACT AGAGGATCAT AATCAG

Fig. 31

Nucleotide sequence of CryIA(c)-RTB1 in pFASTBAC1 : Seq ID No 9

```

1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAAACCTAT
51  AAATATTCCG GATTATTTCAT ACCGTCCCAC CATCGGGCGC GGATCCATGG
101  ACAACAAACCC AAACATCAAC GAATGCATTC CATACAACCTG CTTGAGTAAC
151  CCAGAAGTTG AAGTACTTGG TGGAGAACGC ATTGAAACCG GTTACACTCC
201  CATCGACATC TCCTTGTCCT TGACACAGTT TCTGCTCAGC GAGTTCGTGC
251  CAGGTGCTGG GTTCGTTCTC GGACTAGTTG ACATCATCTG GGGTATCTTT
301  GGTCCATCTC AATGGGATGC ATTCCGGTG CAAATTGAGC AGTTGATCAA
351  CCAGAGGATC GAAGAGTTCC CCAGGAACCA GCCCATCTCT AGGTTGGAAG
401  GATTAGCAA TCTCTACCAA ATCTATGCAG AGAGCTTCAG AGAGTGGAA
451  GCCGATCCTA CTAACCCAGC TCTCCGCGAG GAAATGCGTA TTCAATTCAA
501  CGACATGAAC AGCGCCTTGA CCACAGCTAT CCCATTGTTC GCAGTCCAGA
551  ACTACCAAGT TCCTCTCTTG TCGTGTACG TTCAAGCAGC TAATCTTCAC
601  CTCAGCGTGC TTCGAGACGT TAGCGTGTTT GGGCAAAGGT GGGGATTCGA
651  TGCTGCAACC ATCAATAGCC GTTACAACGA CCTTACTAGG CTGATTGGAA
701  ACTACACCGA CCACGCTGTT CGTTGGTACA ACACTGGCTT GGAGCGGTGC
751  TGGGGTCCTG ATTCTAGAGA TTGGATTAGA TACAACCACT TCAGAGAGAGA
801  ATTGACCCTC ACAGTTTGG ACATTGTGTC TCCTTCCCG AACTATGACT
851  CCAGAACCTA CCCTATCCGT ACAGTGTCCC AACTTACCAG AGAAATCTAT
901  ACTAACCCAG TTCTTGAGAA CTTGACGCT AGCTTCCGTG GTTCTGCCA
951  AGGTATCGAA GGCTCCATCA GGAGCCACA CTTGATGGAC ATCTTGAACA
1001  GCATAACTAT CTACACCGAT GCTCACAGAG GAGAGTATTA CTGGTCTGGA
1051  CACCAGATCA TGGCCTCTCC AGTTGGATTG AGCGGGCCCG AGTTTACCTT
1101  TCCTCTCTAT GGAACATATG GAAACGCCGC TCCACAACAA CGTATCGTTG
1151  CTCAACTAGG TCAGGGGTGC TACAGAACCT TGTCTTCCAC CTTGTACAGA

```

Fig. 31 (Cont ...)

1201 AGACCCCTTCA ATATCGGTAT CAACAACCAG CAACCTTTCG TTCTTGACGG
 1251 AACAGAGTTC GCCTATGGAA CCTCTTCTAA CTTGCCATCC GCTGTTTACA
 1301 GAAAGAGCGG AACCGTTGAT TCCTTGGACG AAATCCCACC ACAGAACAC
 1351 AATGTGCCAC CCAGGCAAGG ATTCTCCAC AGGTTGAGCC ACGTGTCCAT
 1401 GTTCGTTCC GGAATCAGCA ACAGTTCCGT GAGCATCATC AGAGCTCCTA
 1451 TGTTCTCTTG GATACACCGT AGTGCTGAGT TCAACAACAT CATCGCATCC
 1501 GATAGTATTA CTCAAATCCC TGCAGTGAAG GGAAACTTTC TCTTCAACGG
 1551 TTCTGTCAAT TCAGGACCAG GATTCACTGG TGGAGACCTC GTTAGACTCA
 1601 ACAGCAGTGG AAATAACATT CAGAATAGAG GGTATATTGA AGTTCCAATT
 1651 CACTTCCCAT CCACATCTAC CAGATATAGA GTTCGTGTGA GGTATGCTTC
 1701 TGTGACCCTT ATTCACCTCA ACGTTAATTG GGGTAATTCA TCCATCTTCT
 1751 CCAATACAGT TCCAGCTACA GCTACCTCCT TGGATAATCT CCAATCCAGC
 1801 GATTTCCGTT ACTTTGAAAG TGCCAAATGCT TTTACATCTT CACTCGGTAA
 1851 CATCGTGGGT GTTAGAAACT TTAGTGGGAC TGCAGGAGTG ATTATCGACA
 1901 GATTGAGTT CATTCCAGTT ACTGCAACAC TCGAGGCTGA ATGAGAATTC
 1951 ATGCTGATGT TTGTATGGAT CCTGAGCCCA TAGTGCGTAT CGTAGGTCGA
 2001 AATGGTCTAT GTGTTGATGT TAGGGATGGA AGATTCCACA ACGGAAACGC
 2051 AATACAGTTG TGGCCATGCA AGTCTAATAC AGATGCAAAAT CAGCTCTGGA
 2101 CTTTGAAAAG AGACAATACT ATTGATCTA ATGGAAGTG TTTAACTACT
 2151 TACGGGTACA GTCCGGGAGT CTATGTGATG ATCTATGATT GCAATACTGC
 2201 TGCAACTGAT GCCACCCGCT GGCAAATATG GSATAATGGA ACCATCATAA
 2251 ATCCAGATC TAGTCTAGTT TTAGCAGCGA CATCAGGGAA CAGTGGTACC
 2301 ACACTTACGG TGCAAAACAA CATTATGCC GTTAGTCAAG GTTGGCTTCC
 2351 TACTAATAAT ACACAACCTT TTGTTACAAC CATTGTTGGG CTATATGGTC
 2401 TGTGCTTGCA AGCAAAATAGT GGACAAGTAT GGATAGAGGA CTGTAGCAGT
 2451 GAAAAGCGCT AACACAGTG GGCTCTTTAT GCAGATGGTT CAATACGTCC
 2501 TCAGCAAAAC CGAGATAAAT GCCTTACAAG TGATTTAAT ATACGGGAAA
 2551 CAGTTGTTAA GATCCTCTCT TGTGGCCCTG CATCCTCTGG CCAACGATGG
 2601 ATGTTCAAGA ATGATGGAAC CATTTTAAAT TTGTATAGTG GATTGGTGT
 2651 AGATGTGAGG CGATCGGATC CGAGCCTTAA ACAATCATT CTTTACCCTC
 2701 TCCATGGTGA CCCAAACCAA ATATGGTTAC CATTATTTTG ATAGACAGAT
 2751 TACAAGCTTG TCGAGAAGTA CTAGAGGATC ATAATCAG

Fig. 3j

Nucleotide sequence of CryIA(c)-RTB2 in pFASTBAC1: Seq ID No 10

```

1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATTCCG GATTATTCAAT ACCGTCCAC CATCGGCGC GGATCCATGG
101  ACAACAACCC AAACATCAAC GAATGCATTC CATACAACTG CTTGAGTAAAC
151  CCAGAAAGTTG AAGTACTTGG TGGAGAACGC ATTGAAACCG GTTACACTCC
201  CATCGACATC TCCTTGTCCT TGACACAGTT TCTGCTCAGC GAGTTCGTGC
251  CAGGTGCTGG GTTCGTTCTC GGACTAGTTG ACATCATCTG GGGTATCTTT
301  GGTCCATCTC AATGGGATGC ATTCTCGTGC CAAATTGAGC AGTTGATCAA
351  CCAGAGGATC GAAGAGTTGC CCAGGAACCA GGCCATCTCT AGGTTGGAAG
401  GATTGAGCAA TCTCTACCAA ATCTATGCAG AGAGCTTCAG AGAGTGGGAA
451  GCCGATCCTA CTAACCCAGC TCTCCGCGAG GAAATGCGTA TTCAATTCAA
501  CGACATGAAC AGCGCCTTGA CCACAGCTAT CCCATTGTTG GCAGTCCAGA
551  ACTACCAAGT TCCTCTCTTG TCCGTGTACG TTCAAGCAGC TAATCTTCAC
601  CTCAGCGTGC TTCGAGACGT TAGCGTGTTC GGGCAAAGST GGGGATTGGA
651  TGCTGCAACC ATCAATAGCC GTTACAACGA CCTTACTAGG CTGATTGGAA
701  ACTACACCGA CCACGCTGTT CGTTGTGACA ACCTGGCTTT GGAGCGTGTC
751  TGGGGTCCGT ATTCTAGAGA TTGGATTAGA TACAACCACT TCAGAGAGAGA
801  ATTGACCCTC ACAGTTTGG ACATTGTGTC TCTCTCCCG AACTATGACT
851  CCAGAACCTA CCCTATCCGT ACAGTGTCCC AACTTACCAG AGAAATCTAT
901  ACTAACCCAG TTCTTGAGAA CTTGACGGT AGCTTCCGTG GTTCTGCCCA
951  AGGTATCGAA GGCTCCATCA GGAGCCACA CTTGATGGAC ATCTTGAACA
1001 GCATAACTAT CTACACCGAT GCTCAGAGAG GAGAGTAITA CTGCTCTGGA
1051 CACCAGATCA TGGCCTCTCC AGTTGGATTG AGCGGGCCCG AGTTTACCTT
1101 TCCTCTCTAT GGAACATAGG GAAACGCCGC TCCACAACAA CGTATCGTTG
1151 CTCAACTAGG TCAGGGTGTC TACAGAACCT TGTCTTCCAC CTTGTACAGA

```

Fig. 3j (Cont ...)

1201 AGACCCCTTCA ATATCGGTAT CAACAACCAG CAACTTTCCG TTCTTGACGG
1251 AACAGAGTTC GCCTATGGAA CCTCTTCTAA CTTGCCATCC GCTGTTTACA
1301 GAAAGAGCGG AACCGTTGAT TCCTTGACG AAATCCCACC ACAGAACAAAC
1351 AATGTGCCAC CCAGGCAAGG ATTCTCCAC AGGTTGAGCC ACGTGTCCAT
1401 GTTCCGTTCC GGATTCAGCA ACAGTTCGGT GAGCATCATC AGAGCTCCTA
1451 TGTCTCTTGG GATACACCGT AGTGCTGAGT TCAACAACAT CATCGCATCC
1501 GATAGTATTA CTCAAATCCC TGCAGTGAAG GAAACTTTT TCTTCAACGG
1551 TTCTGTCAAT TCAGGACCAG GATTCACTGG TGGAGACCTC GTTAGACTCA
1601 ACAGCAGTGG AATAACATT CAGAATAGAG GGTATATTGA AGTTCCAATT
1651 CACTTCCCAT CCACATCTAC CAGATATAGA GTTCGTGTGA GGTATGCTTC
1701 TGTGACCCCT ATTCACCTCA ACGTTAATTG GGGTAATTCA TCCATCTTCT
1751 CCAATACAGT TCCAGCTACA GCTACCTCCT TGGATAATCT CCAATCCAGC
1801 GATTTCGGTT ACTTTGAAAG TGCCAATGCT TTTACATCTT CACTCGGTAA
1851 CATCGTGGGT GTTAGAAACT TTAGTGGGAC TGCAGGAGTG ATTATCGACA
1901 GATTCSAGTT CATTCCAGTT ACTGCAACAC TCGAGGCTGA ATGAGAATTC
1951 ATGCTGATGT TTGTATGGAT CCTGAGCCCA TAGTGCATAT CGTAGGTCGA
2001 AATGGTCTAT GTGTTGATGT TAGGGATGGA AGATTCCACA ACGGAAACGC
2051 AATACAGTTG TGGCCATGCA AGTCTAATAC AGATGCAAAAT CAGCTCTGGA
2101 CTTTGAAAAG AGACAATACT ATTGATCTA ATGGAAGGTG TTAACTACT
2151 TACGGGTACA GTCCGGGAGT CTATGTGATG ATCTATGATT GCAATACTGC
2201 TGCAACTGAT GCCACCCGCT GGCMAATATG GGATAATGGA ACCATCATAA
2251 ATCCAGATC TAGTCTAGTT TTAGCAGCGA CATCAGGGAA CAGTGGTACC
2301 ACACCTACGG TGCAAACCAA CATTTATGCC GTTAGTCAAG GTTGGCTTCC
2351 TACTAATAAT ACACAACCTT TTGTTACAAC CATGTGTTGG CTATATGGTC
2401 TGTGCTTGCA AGCAAATAGT GGACAAGTAT GGATAGAGGA CTGTAGCAGT
2451 GAAAAGGCTG AACAAACAGT GGCTCTTTAT GCAGATGGTT CAATACGTCC
2501 TCAGCAAAAC CGAGATAATT GCCTTACAAG TGATTTCAAT ATACGGGAAA
2551 CAGTTGTTAA GATCCTCTCT TGTGGCCCTG CATCCTCTGG CCAACGATGG
2601 ATGTTCAAGA ATGATGGAAC CATTTTAAAT TTGTATAGTG GATTGGTGTT
2651 AGATGTGAAG CTGTGCGAGA AGTACTAGAG GATCATAATC AG

Fig. 3k

Nucleotide sequence of CryIA(c)-RTB3 in pFASTBAC1 : Seq ID No 11

```

1  AAATAAGTAT TTTACTGTTT TCGTAACAGT TTTGTAATAA AAAAACCTAT
51  AAATATTCCG GATTATTTCAT ACCGTCCCAC CATCGGGCGC GGATCCATGG
101  ACAACAACCC AAACATCAAC GAATGCATTG CATAACAATG CTGAGTAAC
151  CCAGAAGTTG AAGTACTTGG TGGAGAACGC ATTGAAACCG GTTACACTCC
201  CATCGACATC TCCTTGTCCT TGACACAGTT TCTGCTCAGC GAGTTCGTGC
251  CAGGTGCTGG GTTCGTCTC GGAAGTAGTT ACATCATCTG GGGTATCTTT
301  GGTCCATCTC AATGGGATGC ATTCTGGTGG CAAATTGAGC AGTTGATCAA
351  CCAGAGGATC GAAGAGTTGG CCAGGAACCA GGCATCTCT AGGTTGGAAG
401  GATTGAGCAA TCTCTACCAA ATCTATGCAG AGAGCTTCAG AGAGTGGGAA
451  GCGATCCCTA CTAACCCAGC TCTCCGCGAG GAAATGCGTA TTCAATTCAA
501  CGACATGAAC AGCGCCTTGA CCACAGCTAT CCCATTGTTG GCAGTCCAGA
551  ACTACCAAGT TCCTCTCTTG TCCGTGTACG TTCAAGCAGC TAATCTTCAC
601  CTCACGGTGC TTCGAGACGT TAGCGTGTTT GGGCAAAGGT GGGGATTGGA
651  TGCTGCAACC ATCAATAGCC GTTACAACGA CCTTACTAGG CTGATTGGAA
701  ACTACACCGA CCACGCTGTT CGTTGGTACA ACACTGGCTT GGAGCGTGTG
751  TGGGGTCCCTG ATTCTAGAGA TTGGATTAGA TACAACCAGT TCAGGAGAGA
801  ATTGACCCTC ACAGTTTGG ACATTGTGTC TCTCTTCCG AACTATGACT
851  CCAGAACCTA CCCTATCCGT ACAGTGTCCC AACTTACCAG AGAAATCTAT
901  ACTAACCCAG TTCTTGAGAA CTTGACGGT AGCTTCCGTG GTTCTGCCCA
951  AGGTATCGAA GGCTCCATCA GGAGCCCACA CTTGATGGAC ATCTTGAACA
1001  GCATTAATAT CTACACCGAT GCTCACAGAG GAGAGTATTA CTGGCTGGA
1051  CACCAGATCA TGGCCTCTCC AGTTGGATTG AGCGSGCCG AGTTTACCTT
1101  TCCTCTCTAT GGAACATATG GAAACGCCG TCCACAACAA CGTATCGTTG
1151  CTCAACTAGG TCAGGGTGTG TACAGAACCT TGTCTTCCAC CTGTGACAGA

```

Fig. 3k (Cont...)

1201 AGACCCCTTCA ATATCGGTAT CAACAACCAG CAACTTTCCG TTCTTGACGG
1251 AACAGAGTTC GCCTATGGAA CCTCTTCTAA CTTGCCATCC GCTGTTTACA
1301 GAAAGAGCGG AACCGTTGAT TCCTTGGACG AAATCCCACC ACAGAACAAC
1351 AATGTGCCAC CCAGGCAAGG ATTCTCCAC AGGTTGAGCC ACGTGTCCAT
1401 GTTCCGTTCG GGATTCAGCA ACAGTTCCGT GAGCATCATC AGAGCTCCTA
1451 TGTTCTCTTG GATACACCGT AGTGCTGAGT TCAACAACAT CATCGCATCC
1501 GATAGTATTA CTCAAATCCC TGCAGTGAAG GGAACCTTC TCTTCAACGG
1551 TTCTGTCATT TCAGGACCAG GATTCACTGG TGGAGACCTC GTTAGACTCA
1601 ACAGCAGTGG AAATAACATT CAGAATAGAG GGTATATTGA AGTTCCAATT
1651 CACTTCCCAT CCACATCTAC CAGATATAGA GTTCGTGTGA GGTATGCTTC
1701 TGTGACCCCT ATTCACCTCA ACGTTAATTG GGGTAATTCA TCCATCTTCT
1751 CCAATACAGT TCCAGCTACA GCTACCTCCT TGGATAATCT CCAATCCAGC
1801 GATTTCGGTT ACTTTGAAAG TGCCAATGCT TTACATCTT CACTCGGTAA
1851 CATCGTGGGT GTTAGAAACT TTAGTGGGAC TGCAGGAGTG ATTATCGACA
1901 GATTCGAGTT CATTCAGTT ACTGCAACAC TCGAGGCTGA ATGAGAAITC
1951 ATGCTGATGT TTGTATGGAT CCTGAGCCCA TAGTGCATAT CGTAGTCTGA
2001 AATGGTCTAT GTGTGTATGT TAGGGATGGA AGATTCCACA ACGGAAACGC
2051 AATACAGTTG TGGCCATGCA AGTCTAATAC AGATGCAAAAT CAGCTCTGGA
2101 CTTTGAAAG AGACAATACT ATTTCGATCTA ATGGAAAGTG TTTAACTACT
2151 TACGGGTACA GTCCGGGAGT CTATGTGATG ATCTATGATT GCAATACTGC
2201 TGCAACTGAT GCCACCCGCT GGCMAATATG GGATAATGGA ACCATCATAA
2251 ATCCCAGATC TAGTCTAGTT TTAGCAGCGA CATCAGGAA CAGTGTACC
2301 ACACCTACGG TGCAAAACCA CATTTATGCC GTTAGTCAAG GTTGGCTTCC
2351 TACTAATAAT ACACAACCTT TTGTTACAAC CATGTGTGGG CTATATGGTC
2401 TAAGCTTGTG GAGAAGTACT AGAGGATCAT AATCAG

DECLARATION OF POWER OF ATTORNEY AND POWER TO INSPECT

As a below named inventor, I hereby declare:

that my residence, post office address and citizenship are as stated below next to my name;

that I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention entitled: **PESTICIDAL FUSIONS** the specification of which (check one(s) applicable)

X was filed 27 April 2000 as International Patent Application No. PCT/GB00/01633, on which U.S. National Stage Application No. 09/980,650 is based; and/or
_____ was amended by Amendment filed _____ (if applicable); and/or
_____ is attached to this Declaration, Power of Attorney and Power to Inspect;

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and

that I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Rule 56(a) [37 C.F.R. §1.56(a)].

CLAIM UNDER 35 U.S.C. §119: I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application of which priority is claimed:

Prior Foreign Application(s) Appln No.	Country	Filing Date Day-Mon-Year	Priority Claimed Yes - No
9909796.6	Great Britain	28-04-1999	Yes

POWER OF ATTORNEY: As inventor, I hereby appoint **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania, and the following individual(s) as my attorneys or agents with full power of substitution to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith: **Patrick J. Hagan, Reg. No. 27,643** and **Kathleen D. Rigaut, Ph.D., Reg. 43,947.**

POWER TO INSPECT: I hereby give **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania or its duly accredited representatives power to inspect and obtain copies of the papers on file relating to this application.

SEND CORRESPONDENCE TO:

CUSTOMER NUMBER 000110

DIRECT INQUIRIES TO:

Telephone: (215) 563-4100
Facsimile: (215) 563-4044

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SOLE OR FIRST JOINT INVENTOR

SECOND JOINT INVENTOR (IF ANY)

1-00
Full Name Paul Christou
First Middle Last
Signature P. Christou
Date JANUARY 20, 2002
Residence Norwich UK GBX
City State or Country
Citizenship USA
Post Office Address:
38 GLENALMOND
Street Address
City Norwich State or Country NR4 6AG Zip Code

2-00
Full Name Luke Mehlo
First Middle Last
Signature L. Mehlo
Date 28 JANUARY 2002
Residence HARARE ZIMBABWE ZWX
City State or Country
Citizenship ZIMBABWEAN
Post Office Address:
SIRDC BOX 6640 / 1574 AIRES ROAD, HARARE
Street Address
City HARARE State or Country ZIMBABWE Zip Code

SEQUENCE LISTING

<110> Christou, Paul
Mehlo, Luke

<120> Pesticidal Fusions

<130> 0380-P02714US0

<140> US 09/980,650

<141> 2001-10-26

<150> PCT/GB00/01633

<151> 2000-04-27

<150> GB 9909796.6

<151> 1999-04-28

<160> 19

<170> PatentIn Ver. 2.1

<210> 1

<211> 2062

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleotide
sequence of CryIA(b) in pFASTBAC1

<400> 1

```

aaataagtat tttactgttt tcgtaacagt tttgtaataa aaaaacctat aaatattccg 60
gattattcat accgtccac catcgggcgc ggatccatgg acaacaaccc aaacatcaac 120
gaatgcattc catacaactg cttgagtaac ccagaagtgg aagtactttg tggagaaacg 180
attgaaaccc gttacaactc catcgacatc tccttgtcct tgacacagtt tctgtccaag 240
gagttcgtgc caggtgctgg gttcgttctc ggactagttg acatcatctg gggtatcttt 300
ggtecatctc aatgggatgc attcctgggt caaattgagc agttgatcaa ccagaggatc 360
gaagagttcg ccaggaaacca ggccatctct aggttggaag gattgagcaa tctctacca 420
atctatgcag agagcttcag agagtgggaa gccgatcccta ctaacccagc tctccgcgag 480
gaaatgcgta ttcaattcaa cgacatgaac agcgcttga ccacagctat cccattgttc 540
gcagtcacga actaccaagt tctctctctg tccgtgtacg ttcaagcagc taatcttcac 600
ctcagcgtgc ttcgagacgt tagcgtgttt gggcaaaagg ggggattcga tgctgcaacc 660
atcaatagcc gttacaacga ccttactagg ctgattggaa actacaccca ccacgctgtt 720
cggtgggtaca acactggctt ggagcgtgtc tggggtccgt attctagaga ttggattaga 780
tacaaccagt tcaggagaga attgaccctc acagttttgg acattgtgtc tctcttcccg 840
aactatgact ccagaacctc cctatccgtg acagtgtccc aacttaccag agaaatctat 900
actaaccagc ttcttgagaa cttcgacggt agcttcctgt gttctgccca aggtatcgaa 960
ggctccatca ggagcccaca cttgatggac atcttgaaca gcataactat ctacacagat 1020
gctcacagag gagagtatta ctgggtctgga caccagatca tggcctctcc agttggattc 1080
agcgggcccc agtttaacct tctctctctat ggaactatgg gaaacgccgc tccacaacaa 1140
cgtatcgttg ctcaactagg tcagggtgtc tacagaacct tgtcttccac cttgtacaga 1200
agacccttca atatcgggat caacaaccag caactttccc ttcttgacgg aacagagttc 1260
gcctatggaa cctcttctaa cttgccatcc aatgtttaca gaaagacggg aaccgttgat 1320
tccttggagc aaatcccacc acagaacaac agtgtgccac ccaggcaagg attctccac 1380
agggttgagc acgtgtccat gttccgttcc ggattcagca acagtccctg gagcatcatc 1440

```

agagctccta	tgtttctatg	gattcatcgt	agtgcgtgagt	tcaacaatat	cattctctcc	1500
tctcaaatca	cccaaatccc	attgaccaag	tctactaacc	ttggactctgg	aactctctgc	1560
gtgaaaggac	caggcttcac	aggaggtgat	attcttagaa	gaactctctcc	tggccagatt	1620
agcacctcca	gagttaacat	cactgcacca	ctttctcaaa	gatatcgtgt	caggattcgt	1680
taccgactcta	ccactaaact	gcaattccac	acctccatcg	acgggaaggcc	tatcaatcag	1740
ggtaacttct	cgcgaaccat	gtcaaagcgg	agcaacttgc	aatccgcgac	cttcagaacc	1800
gtcgggtttca	ctactccttt	caactttctct	aacggatcaa	cggtttttcac	ccttagcgct	1860
catgtgtttca	attctggcaa	tgaagtgtac	attgaccgta	ttgagtttgt	gcttcgcgaa	1920
gttacctctcg	aggctgagta	ctgagaattc	aaaggcctac	gtcgacgagc	tcactagtctg	1980
cggccgcttt	cgaatctaga	gcctgcagtc	tcgaggcatg	cggtaccaag	cttgtcgaga	2040
agtactagag	gatcataatc	ag				2062

<210> 2

<211> 2062

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleotide sequence of CryIA(c) in pFASTBAC1

<400> 2

aaataagtat	tttactgttt	tcgtaacagt	tttgaataaa	aaaaacctat	aaatatctcg	60
gattattcat	accgtccccc	catcgggcgc	ggatccatgg	acaacaaccc	aaacatacac	120
gaatgcattc	catacaacct	cttgagtaac	ccagaagttg	aagtactctgg	tggagaacgc	180
attgaaaacc	gttacactcc	catcgacatc	tccttgtctc	tgacacagtt	tctgtctcgc	240
gagttctgtc	caggtgtctg	gttcgtttct	ggactagtgt	acatcatctg	gggttatctt	300
ggctccattc	aatgggagtc	attcctgggt	caaattgagc	agttgatcaa	ccagaggatc	360
gaagagttcg	ccaggaaccca	ggccatctct	aggttggaag	gattgagcaa	tctctaccaa	420
atctatgcag	agagcttccg	agagtgggaa	gccgatccta	ctaaccagcg	tctccgcgag	480
gaaatgcgta	ttcaattcaa	cgacatgaac	agcgctctga	ccacagctat	cccattgttc	540
cgagtcacga	actaccaagt	tcctctcttg	tcctgttaac	ttcaagcagc	taattctcac	600
ctcagcgtgc	ttcgagacgt	tagcgtgttt	gggcaaaagt	ggggattcga	tgtctgaacc	660
atcaatagcc	gtttacaacga	ccttactagg	ctgattggaa	actacacggc	ccacgtgtgt	720
cgttggtaca	acaactgctt	ggagcgtgtc	tggggtcctg	attctagaga	ttggattaga	780
tacaacacgt	tcaggagaga	attgaccttc	acagttttgt	acattgtgtc	tctcttcccg	840
aactatgact	ccagaaacct	ccctatccgt	acagtgctcc	aacttaccag	agaaaatcat	900
actaacccag	ttcttgagaa	cttcgacggt	agcttccgtg	gttctgccca	aggtatcgaa	960
ggctccatca	ggagcccaca	cttgatggac	atcttgaaac	gcataacctat	ctacacagct	1020
gctccacagag	gagagtatta	ctggcttgga	caccagatca	tggcctctcc	agttggattc	1080
agccggcccg	agtttaacct	tcctctctat	ggaaactatg	gaaacgcgcg	tccacaacaa	1140
cgatatcgtt	ctcaactagg	tcagggtgtc	tacagaacct	tgtcttccac	cttgtacaga	1200
agacccttca	atatcggtag	caacaaccag	caactttccg	tcttggacgc	ccaagagtct	1260
gcctatggaa	cctcttctaa	cttgccatcc	gctgtttaca	gaaagagcgg	aaccgttgtat	1320
tccttggagc	aaatcccaac	acagaaacac	aatgtgccac	ccaggcaagg	attctccccc	1380
aggttgagcc	acgtgtccat	gttcggttcc	ggattccaga	acagttcccg	gagcatccat	1440
agagctccta	tggtctcttg	gatacacctg	agtgctgagt	tcaacaacat	catcgcatcc	1500
gatgatttta	ctcaaatccc	tgcagtgaa	ggaaactttc	tcttcaacgg	tctctgattc	1560
tcaggaccag	ggttcaactg	tggagacctc	gttagactca	acagcagttg	aaataaacat	1620
cagaatagag	ggatatattg	agttccaatt	caacttccat	ccacatctac	cagatataga	1680
ttctcgttgt	ggatatcttc	tgtgacctct	attcacctca	acgttaattg	gggttaattca	1740
gctactctct	ccaatacagt	tccagctaca	gctacctcct	tggataatct	ccaatccagc	1800
gatttcgggt	actttgaaag	tgccaatgct	tttacctctt	caactcgttaa	catcgtgggt	1860
gttgaaaact	ttagtgggag	tgcaggagtg	attatcgaca	gattcgagtt	cattccagtt	1920
actgcaaac	tcgaggctga	atgagaattc	aaaggcctac	gtcgacgagc	tcactagtctg	1980
cggccgcttt	cgaatctaga	gcctgcagtc	tcgaggcatg	cggtaccaag	cttgtcgaga	2040

agtactagag gatcataatc ag

2062

<210> 3
 <211> 956
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Nucleotide
 sequence of RTB1 in pFASTBAC1

<400> 3
 aaataagtat tttactgttt tcgtaacagt tttgtaataa aaaaacccat aaatattccg 60
 gattattcat acogtcccac catcgggcgc ggatcccggt ccgaagcgcg cggaattcat 120
 gctgatgttt gtatggatcc tgagcccata gtgcgtatcg taggtcgaaa tggctcatgt 180
 gttgatgtta gggatggaag attccacaac ggaaacgcaa tacagttgtg gccatgcaa 240
 tctaatacac atgcaaatca gctctggact ttgaaaagag acaatactat tcatgtctaa 300
 ggaaagtgtt taactactta cgggtacagt ccgggagctc atgtgatgat ctatgattgc 360
 aatactgctg caactgatgc caccgcgtgg caaatatggg ataattggaac catcataaat 420
 ccagatctca gtctagtttt agcagcgaca tcagggaaca gtggtaccac acttacggtg 480
 caaaccaaca tttatgccgt tagtcaaggt tggcttccta ctaataatc acaacctttt 540
 ttacaacca ttgttggcgt atatggtctg tgcttgcaag caaatagtgg acaagtatgg 600
 atagaggact gtacagtgga aaaggctgaa caacagtggg ctctttagtc agatggttca 660
 atacgtcttc agcaaaaccg agataattgc cttacaagtg attctaatat acgggaaaca 720
 gttgtcaaga tctctcttgg tggccctgca tctctggcc aacgatggat gttcaagaat 780
 gatggaacca ttttaaatgt gtatagtggg ttggtgttag atgtgagggc atcggatccg 840
 agccttaaac aaatcattct ttacctctc catggtgacc caaaccaaat atggttacca 900
 ttattttgat agacagatta caagcttgte gagaagtact agaggatcat aatcag 956

<210> 4
 <211> 860
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Nucleotide
 sequence of RTB2 in pFASTBAC1

<400> 4
 aaataagtat tttactgttt tcgtaacagt tttgtaataa aaaaacccat aaatattccg 60
 gattattcat acogtcccac catcgggcgc ggatcccggt ccgaagcgcg cggaattcat 120
 gctgatgttt gtatggatcc tgagcccata gtgcgtatcg taggtcgaaa tggctcatgt 180
 gttgatgtta gggatggaag attccacaac ggaaacgcaa tacagttgtg gccatgcaa 240
 tctaatacac atgcaaatca gctctggact ttgaaaagag acaatactat tcatgtctaa 300
 ggaaagtgtt taactactta cgggtacagt ccgggagctc atgtgatgat ctatgattgc 360
 aatactgctg caactgatgc caccgcgtgg caaatatggg ataattggaac catcataaat 420
 ccagatctca gtctagtttt agcagcgaca tcagggaaca gtggtaccac acttacggtg 480
 caaaccaaca tttatgccgt tagtcaaggt tggcttccta ctaataatc acaacctttt 540
 ttacaacca ttgttggcgt atatggtctg tgcttgcaag caaatagtgg acaagtatgg 600
 atagaggact gtacagtgga aaaggctgaa caacagtggg ctctttagtc agatggttca 660
 atacgtcttc agcaaaaccg agataattgc cttacaagtg attctaatat acgggaaaca 720
 gttgtcaaga tctctcttgg tggccctgca tctctggcc aacgatggat gttcaagaat 780
 gatggaacca ttttaaatgt gtatagtggg ttggtgttag atgtgaagct tgcgcagaag 840
 tactagagga tcaataatcag

<210> 5
 <211> 604
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Nucleotide
 sequence of RTB3 in pFASTBAC1

<400> 5
 aaataagtat tttactgttt tcgtaacagt tttgtaataa aaaaacctat aaatattccg 60
 gattattcat accgtcccac catcgggcgc ggatcccggt ccgaagcgcg cgggaattcat 120
 gctgatgttt gtatggatcc tgagcccata gtgcgtatcg taggtcgaaa ttggtctatgt 180
 gttgatgtta gggatggaag attccacaac ggaacgcgaa tacagttgtg gccatgcaag 240
 tctaatacac atgcaaatca gctctggact ttgaaaagag acaatactat tcgatctaat 300
 ggaagtggtt taactactta cgggtacagt ccgggagtgct atgtgatgat ctatgattgc 360
 aatactgctg caactgatgc caccgcgtgg caaatatggg ataattggaac catcataaat 420
 cccagatcta gtctagtttt agcagcgaca tcagggaaca gtggtaccac acttacgggtg 480
 caaaccaaca tttatgcgct tagtcaagggt tggtctccta ctaataatac acaacctttt 540
 gttacaacca ttgttgggct atatggtcta agcttgcga gaagtactag aggatcataa 600
 tcag 604

<210> 6
 <211> 2788
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Nucleotide
 sequence of CryIA(b)-RTB1 in pFASTBAC1

<400> 6
 aaataagtat tttactgttt tcgtaacagt tttgtaataa aaaaacctat aaatattccg 60
 gattattcat accgtcccac catcgggcgc ggatccatgg acaacaaccc aaacatcaac 120
 gaatgcattc catacaactg cttgagtaac ccagaagttg aagtaacttg tggagaacgc 180
 attgaaaccg gttacactcc catcgacatc tccttgcctc tgacacagtt tctgctcagc 240
 gagttcgtgc caggtgctgg gttcgttctc ggactagttg acatcatctg gggatctctt 300
 ggtccatctc aatgggatgc attcctgggt caaattgagc agttgatcaa ccagaggatc 360
 gaagagtctc ccaggaaacca ggccatctct aggttggaa gattgagcaa tctctacca 420
 atctatcgag agagcttcag agagtgggaa gccgatccta ctaccaccgc tctccgcgag 480
 gaaatcgcta ttcaattcaa cgacatgaac agcgcccttg ccacagctat cccattgttc 540
 cgagtcgaga actaccaggt tcctctcttg tcctgtgaac ttcaagcagc taactctcac 600
 ctacagctgc ttcgagacgt tagcgtgttt gggcaaaagg ggggattcga tgcgcgaacc 660
 atcaatagcc gttacaacga ccttactagg ctgattggaa actacacoga ccacgctgtt 720
 cggttggtaca acactgggtc ggagcgtgtc tggggctcgt attctagaga ttcgattaga 780
 tacaaacagt tcaggagaga attgacctc acagtttggg acattgtgtc tctctcccg 840
 aactatgact ccagaacctc cctatccggt acagttgtcc aacttaccag agaaatctat 900
 actaaccagc ttcttgagaa cttcgacggt agcttccgtg gttctgcoca aggtatcgaa 960
 ggctccatca ggagccacaa ctgtatggac atcttgaaca gcataaactat ctacaccgat 1020
 gctcacagag gagagatta ctggtctgga caccagatca tggcctctcc agttggattc 1080
 agcgggcgcc agtttaacct tcctctctat ggaactatgg gaaacgcgcg tccacaacaa 1140
 cgatcgtgtg ctcaactagg tcagggtgtc tacagaacct tgtctctcac ctgttcagaa 1200
 agacccttca atatcgttat caacaaccag caactttccg ttcttgacgg aacagagtgc 1260
 gctatggaa cctcttctaa cttgccatcc gctgtttaca gaaagagcgg aacctgtgat 1320
 tccttggagc aaatcccacc acagaaacac aatgtgccac ccaggcaagg attctccac 1380
 aggttgagcc acgtgtccat gttccgttcc ggattcagca acagttccgt gagcatcate 1440

```

agagctccta tgtttcatg gattcatcgt agtgcgtagt tcaacaatat cttctcttcc 1500
tctcaaatca cccaaatccc attgaccaag tctactaacc ttggatctgg aactctctgc 1560
gtgaaaggac caggctccac aggaggtgat attcttagaa gaacttctcc tggccagatt 1620
agcacctcca gagttaacat cactgcacca ctttctcaaa gatatcgtgt caggattcgt 1680
tacgcattca ccaactacat gcaattccac accctccatcg acggaaggcc tatcaatcag 1740
ggtaacttct cgcgaacctat gtcaacggcg agcaacttgc aatccggcag cttcagaacc 1800
gtcgggttca ctactccttt caactctctc aacggatcaa gcgttttccac ccttagcgct 1860
catgtgttca attctggcaa tgaagtgtac attgaccgta ttgagtttgt gcttgcgcaa 1920
gttacctctg aggcgtgagta ctgagaattc atgctgaggt ttgtatggat cctgagccca 1980
tagtgcgtag ctgtaggtcga aatggtctat gtgtgtgagt tagggatgga agattccaaca 2040
acggaaacgc aatacagttg ttggccatgca agtctaatac agatgcaaat cagctctgga 2100
ctttgaaaag agacaatact attctgatcta atggaagtgt ttttaactact tacgggtaca 2160
gtccgggagt ctatgtgatg attctatgatt gcaatactgc tgcaactgat gccaccgct 2220
ggcaaatatg ggataatgga accatcataa atcccagatc tagtctagtt tttagcagca 2280
catcagggaa cagtggtaacc acacttacgg tgcaaaccaa catttatgcc gttagtcaag 2340
gttggtctcc tactaataat acacaacctt ttgttacaac cattgttggg ctatatggtc 2400
tgtgcttgca agcaaatagt ggacaagtat ggatagagga ctgtagcagt gaaaaggctg 2460
aacaacagtg ggcctctttat gcagatgggt caatacgtcc tcagacaatac cgagataaatt 2520
gccttacaag tgattctaat atacgggaaa cagttgttaa gatcctctct ttgtggccctg 2580
catcctctgg ccaacagtagg atgttcaaga atgatggaaac cattttaagt ttgtatagtg 2640
gattggtggt agatgtgagg cgatcggatc cgagccttaa acaaatcatt ctttaccctc 2700
tccattggtg cccaaccaa atatggttac cattattttg atagacagat tacaagcttg 2760
tcgagaagta ctagaggatc ataatacag 2788

```

<210> 7

<211> 2692

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleotide
sequence of CryIA(b)-RTB2 in pFASTBAC1

<400> 7

```

aaataagtat tttactgttt tcgtaacagt tttgtaataa aaaaacctat aaatattccg 60
gattatccat accgtcccac catcggggcg ggatccatgg acaacaacc aaacatacac 120
gaatgcattc cactacaactg cttgagtaac ccagaagttg aagctacttg ttggagaaccg 180
gttgaaacgc gttacactcc catcgacatc tctctgtcct tgacacagtt ttgtctcacc 240
gagttcgtcg cagggtgctgg gttcgttctc acatcatctg gggatctctt 300
gggtccatctc aatgggatgc attcctgggt caaattgagc agttgatcaa ccagaggatc 360
cagagagttcg ccaggaaacca ggccatctct aggttggaa gattgagcaa tctctacca 420
aactatcgag agagcttcag agagtggaag gccgatccta ctaaccagc tctcccgag 480
gaattcgcta tctaattcaa cgacatgaac agcgccctga ccacagctat cccattgttc 540
gcagtcgaga actaccaagt tctctctctt tccgtgtacg ttcaagcagc taattcttcc 600
ctcagcgtgc ttcgagacgt tagcgtgttt gggcaaaagt ggggatctga tgctgcaacc 660
atcaatagcc gttacaacga ccttactagg ctgattggaa actacaccga caccgctgtt 720
cgttggtaca acactggcct ggagcgtgtc tggggctcctg attctagaga ttgattaga 780
tacaacaggt tcaggagaga attgaccctc acagtttttg acattgtgtc tctctcccg 840
actatgactc ccagaaccta cctatccgt acagttgtcc aacttaccag agaaatctat 900
aactaaccag ttcttgagaa cttcgacggt agcttccgtg gttctgcccc aggtatcgaa 960
gggtccatca ggagcccaca cttgatggac atcttgaaca gcataactat ctacaccgat 1020
gtccacagag gagagtatta ctggtctgga caacagatca tggcctctcc agtttgattc 1080
agtcgggccc agtttactct tctctcttat ggaactatgg gaaacgcgcg tccacaacaa 1140
cgatagcttg ctcaactagg ctgaggtgtc tacagaacct ttgtcttccc cttgtacaca 1200
agacccttca atatcgttat caacaaccag caactttccg cttcttagcg aacagagttc 1260
gcctatggaa cctcttctaa cttgccatcc gctgtttaca gaaagagcgg aaccgttgat 1320

```

```

tccttgagc aaatcccacc acagaacaac aatgtgccac ccaggcaagg attctcccac 1380
aggttgagcc acgtgtccat gttccgttcc ggattccaga acagttccgt gagcatcac 1440
agagctccta tgttctcatg gattcatcgt agtgctgagt tcaacaatat cattctctcc 1500
tctcaaatca cccaaatccc attgaccaag tctactaacc ttggatctgg aactctctgc 1560
gtgaaaggac caggcttcac agggagtgat attcttagaa gaactctctcc tggccagatt 1620
agcaccctca gagttaacat cactgcacca ctttctcaaa gatatcgtgt caggattcgt 1680
taccgatcta ccaactaact gcaattccac acctccatcg accggaaggcc tatcaatcag 1740
ggtaactctt ccgcaaccat gtcaagcggc agcaacttgc aatccggcag cttcagaacc 1800
gtcgggttca ctactccttt caacttctct aacggatcaa cgttttccac ccttagcgct 1860
catgtgttca attctggcaa tgaagtgtac attgaccgta ttgagtttgt gcttgccgaa 1920
gttaccttcg aggcgtgagta ctgagaattc atgctgatgt ttgtatggat cctgagccca 1980
tagtgcgatc cgtaggtcga aatggctctat gtgttgatgt tagggatgga agattccaca 2040
acggaaccgc aatacagttg ttggccatgca agtctaatac agatgcaaat cagctctgga 2100
ctttgaaaag agacaatact attcgatcta atggaaagtg ttaactact tacgggtaca 2160
gtccgggagt ctatgtgatg atctatgatt gcaatactgc tgcaactgat gccaccgct 2220
ggcaaatatg ggataatgga accatcataa atcccgactg tagtctagtt tttagcagca 2280
catcagggaa cagtggttacc acacttacgg tgcaaaccaa cattttgccc gttatgcag 2340
tgtggcttcc tactaataat acacaacctt ttgttacaac catgtgtggg ctatatggct 2400
tgtgcttgca agcaaatatt ggacaagtat ggatagagga ctgtagcagt gaaaaggctg 2460
aacaacagtg ggctctctat gcagatggtt caatacgtcc tcagcaaaac cgagataaatt 2520
gccttacaag tgattctaat atacgggaaa cagttgttaa gatcctctct tgtggccctg 2580
catcctctgg ccaacagtg agtttcaaga atgatggaac cattttaat ttgtatagtt 2640
gattgtgtgt agatgtgaa cttgtcgaga agtactagag gatcataatc ag 2692

```

<210> 8

<211> 2436

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleotide
sequence of CryIA(b)-RTB3 in pFASTBAC1

<400> 8

```

aaataagtat tttactgttt tcgtaacagt tttgtaataa aaaaacctat aaattattccg 60
gattattcat accgtcccac catcggggcgc ggatccatgg acaacaaccc aaacatcaac 120
gaatgcattc catacaactc cttgagtaac ccagaagttg aagtaacttg ttggagaacgc 180
attgaaacctg gttacactcc catcgacatc tccttgtcct tgacacagtt ttctgtcctc 240
gagttcgtgc cagtgctctg gttcgttctc ggactagttg acatcatctg gggatctctt 300
ggctcatctc aatgggatgc attcctgggt caaattgagc agttgatcaa ccagaggatc 360
gaagagttcg ccaggaaacca ggccatctct aggttggaa gattgagcaa tctctacca 420
atctatcgag agagcttcag agagtggaag gccgatccta ctaaccagc tcctccgag 480
gaaatcgcta ttcaattcaa cgacatgaac agcgccctga ccacagctat cccattgttc 540
gcagtcacga actaccaagt tcctctcttg tcctgttacg ttcaagcagc taattctcac 600
ctcagcgtgc ttcgagacgt tagcgtgttt gggcaagggt ggggattcga tgctgcaacc 660
atcaatagcc gttacaacga ccttactagg ctgattggaa actacaccaa ccaagctgtt 720
cgttggtaca acactggctt ggagcgtgtc tggggctcctg attctagaga ttgattaga 780
tacaacagtg tcaggagaga attgaccctc acagtttttg acattgtgtc tctctccgc 840
aactatgact ccagaaccta cctatccgt acagttgtcc aacttaccag agaaatctat 900
actaacccag ttcttgagaa cttcgacggt agcttccgtg gttctgccca aggtatcgaa 960
ggctccatca ggagccacca cttgatggac atcttgaaca gcataactat ctacacgat 1020
gctcacagca gagagtatta ctggtctgga caacagatca tggcctctcc agttcgattc 1080
agcgggcccg agtttacctt tcctctctat ggaactatgg gaaacgcgcg tcaccaacaa 1140
cgtatcgttg ctcaactagg tcaggggtgtc tacagaacct tgctctccac cttgtacaga 1200
agacccttca atcttgagat caacaaaccg caactttccg ttcttgacgg aacagagttc 1260
gcctatggaa cctcttctaa cttgccatcc gctgtttaca gaaagagcgg aaccgttgat 1320

```

tccctggagc	aaatccacc	acagaacaac	aatgtgccac	ccaggcaagg	attctccacc	1380
agggttgagc	acgtgtccat	gttccgttcc	ggattcagca	acagttccgt	gagcatcac	1440
agagctccta	tgtttccatg	gattcatcgt	agtgtcgtgt	tcaacaatat	cattctctcc	1500
tctcaaatca	cccaaatccc	attgaccaag	tctactaac	ttggatctgg	aactctctgtc	1560
gtgaaaggca	caggcttcc	aggaggtgat	attcttagaa	gaactctctc	tggcgagatt	1620
agcacctcca	gagtttaacat	cactgcacca	ctttctcaaa	gatactcgtt	caggatctgt	1680
tacgcattca	ccaactaact	gcaattccac	acctccatcg	acggaaagccc	tatcaatcag	1740
ggtaacttct	ccgcaaacat	gtcaagcggc	agcaacttgc	aatccggcag	cttcagaacc	1800
gtcggtttca	ctactctctt	caacttctct	acaggatcaa	gcgttttcc	ccttagcgct	1860
catgtgttca	attctggcaa	tgaagtgtac	attgaccgta	ttgagtttgt	gcctgccgaa	1920
gttaccctcg	aggctgagta	ctgagaattc	atgctgagtg	ttgtatggat	cctgagccca	1980
tagtgcggtat	cgtaggtcga	aatggtctct	gtgtgtgagt	tagggatgga	agattccaca	2040
acggaaacgc	aatacagttg	tggccatgca	agtctaatac	agatgcaaat	cagctctgga	2100
ctttgaaaag	agacaatact	attcgatcta	atggaaagtg	tttaactact	tacgggtaca	2160
gtccgggagt	ctatgtgatg	atctatgatt	gcaatactgc	tgcgaactgat	gccaccgcct	2220
ggcaaatatg	ggataatgga	accatcataa	atcccagatc	tagtctagtt	tttagcagca	2280
ccacagggaa	cagttggtacc	acacttacgg	tgcacaacca	catttatgcc	gttagtcaag	2340
gttggtcttc	tactaataat	acacaacctt	ttgttaacaac	cattgtgtgg	ctatatggtc	2400
taagcttgtc	gagaagtact	agaggatcat	aatcag			2436

<210> 9

<211> 2788

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleotide
sequence of CryIA(c)-RTB1 in pFASTBAC1

<400> 9

aaataagtat	tttactgttt	tcgtaacagt	tttgaataa	aaaaacctat	aaatatccg	60
gattattcat	accgtccac	catcgggcgc	ggatccatgg	acaacaaccc	aaacatcaac	120
gaatgcattc	catacaactg	cttgagtaac	ccagaagttg	aagtacttgg	tggagaacgc	180
attgaaacgg	gttaactctc	catcgacatc	ctctgtccct	tgacacagtt	tctgctcagc	240
gagttcgtgc	caggtgctgg	gttcgttctc	ggactagtgt	acatcatctg	gggtatcttt	300
gggtccatct	aatgggatgc	attcctgggt	caaattgagc	agttgatcaa	ccagaggatc	360
gaagaggttc	ccaggaaacca	ggccatctct	aggttggagg	cttgtagcaa	tctctaccaa	420
attctatcgag	agagcttcag	agagttggaa	gccgatccta	ctaaccaggc	tctccggcag	480
gaaatcgcta	tccaattcaa	cgacatgaac	agcgcccttga	ccacagctat	cccattgttc	540
cgagtcgcaga	actaccaagt	tctctctctg	tccgtgtacg	ttcaagcagc	taactcttcac	600
ctcagctgcgc	tgcagacgt	tagcgtgttt	gggcaaaagt	ggggattcga	tgtcgaacc	660
atcaatagcc	gttacaacga	ccttaactagg	ctgattggaa	actacaccca	ccacgctggt	720
cgttggttaca	acactgtcct	ggagcgtgtc	tggggctcgt	attctagaga	ttaggtatga	780
tacaaccagat	tcaggagaga	attgacccctc	acagtttttg	acattgtgtc	tctctcccg	840
aactatgact	ccagaacctc	ccctatccgt	acagtgctcc	aacttaccag	agaaatctat	900
actaacccag	tcttgagaa	cttcgacggt	agcttccgtg	gttctgccca	aggatccgaa	960
gggtccatca	ggagcccaca	cttgatggac	atcttgaata	gcataacctat	ctacaccgat	1020
gctcacagag	gagagtatta	ctggctctgga	caccagatac	tggcctctcc	agttggattc	1080
agcgggcctcg	agtttaacct	tctctctctat	ggaactatgg	gaaacgcgcg	tccacaacaa	1140
cgtatcggtg	cttaactagg	tcagggtgtc	tacagaacct	tgtcttccac	cttgtacaga	1200
agacccttca	atctcgttat	caacaaccag	caactttccg	tctctgacgg	aacagagttc	1260
ccctatggaa	cctctctcaa	cttgcacatc	gctgttttaca	gaaagagcgg	acacgctgat	1320
tccctggagc	aaatccacc	acagaacaac	aatgtgccac	ccaggcaagg	attctccacc	1380
agggttgagc	acgtgtccat	gttccgttcc	ggattcagca	acagttccgt	gagcatcac	1440
agagctccta	tgttctcttg	gatacacccg	agtgtcgtgt	tcaacaacat	cagctcatcc	1500
gatagtatta	ctcaaatccc	tgcagtgaag	ggaaactttc	tcttcaacgg	tctctgctatt	1560


```

tcaggaccag gattcactgg tggagacctc gttagactca acagcagtgg aaataacatt 1620
cagaatagag ggtatatatga agttccaatt cacttcccat ccacatctac cagatataga 1680
ttctcgtgta ggtatgcttc tgtgaccttc attcacctca acggttaattg gggtaattca 1740
tccatcttct ccaatcacagt tccagctaca gctacctct tggataactct ccaatccagc 1800
gatttcgggtt accttggaaag tgccaatgct ttacatcttt cactcggtaa catcgtgggt 1860
gttagaaact ttagtgggac tgcaggagtg attatcgaca gattcagatt cattccagtt 1920
actgcaacac tcgaggctga atgagaattc atgctgatgt ttgtatggat cctgagccca 1980
tagtgcgat cgtaggctga aatgggtctat gtgttgatgt tagggatgga agatccaca 2040
acggaaaacg aatacagttg tggccatgca agtctaatac agatgcaaat cagctctgga 2100
ctttgaaaag agacaatact attcgatcta atggaagggt ttttaactact tacgggtgca 2160
gtccgggagt ctatgtgatg atctatgatt gcaatactgc tgcaactgct gccaccgct 2220
ggcaaatatg ggataatgga accatcataa atcccagatc tagcttagtt tttagcagca 2280
catcagggaa cagtgttacc acacttacgg tgcaaaccaa catttatgcc gtttagtcaag 2340
gttggtcttc tactaataat acacaacctt ttgttacaac cattgttggg ctatatggtc 2400
tgtgcttgca agcaaatagt ggacaagtat gtagtaggga ctgtagcagt gaanaagctg 2460
aacaacagtg ggctctttat gcagatggtt caatacgtcc tcagcaaac cagagataatt 2520
gccttacaag tgattctaat atacgggaaa cagtgtgtta gatcctctct tgtggccctg 2580
catcctctgg ccaagctgag atgttcaaga atgatggaac cattttaaat ttgtatagtg 2640
gattggtggt agatgtgagg cgatcggatc cgagccttaa acaaatcatt ctttaccctc 2700
tccatgggtg cccaaccaa atatggttac cattattttg atagacagat tacaagcttg 2760
tcgagaagta ctgaggatc ataatacag 2788

```

<210> 10

<211> 2692

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleotide
sequence of CryIA(c)-RTB2 in pFASTBAC1

<400> 10

```

aaataagtat tttactgttt tcgtaacagt tttgtaataa aaaaacctat aaatattccg 60
gattattcat accgtcccac catcgggcgc ggtatccatg acaacaaccc aaacatcaac 120
gaatgcattc catacaactg cttgagtaac ccagaagttg aagtacttgg tggagaacgc 180
attgaaaccc gttacactcc catcgacatc tccttgcctt tgacacagtt tctgtcctac 240
gagttcgtgc caggtgcctg gttcgttctc ggactagttg acatcatctg ggttatcttt 300
ggtcattctc aatgggatgc attcctggtg caaattgagc agttgatcaa ccagaggatc 360
gaagagtctc ccaggaaacca ggccatctct aggttggaa gattgagcaa tctctacca 420
attcatgcag agagcttcag agagtgaggaa gccgatccta ctaaccaccg tctccgcgag 480
gaaatcgcta ttctaattcaa cgacatgaac agcgccttga ccacagatat cccattgttc 540
cgagtcgaga actaccaagt tctctctctg tccgtgtacg ttcaagcagc taattctcac 600
ctcagctgac ttcgagacgt tagcgtgttt gggcaaaagt ggggattcga tgcctgcaac 660
atcaatagcc gttacaacga ccttactagg ctgattggaa actacaccga ccacgtgtgt 720
cgttggtaac actcgggctt ggagcgtgtc tggggctcctg attctagaga ttgattagga 780
tcgaaccagt tcaggagaga attgacctc acagtttttg acattgtgtc tctctcccg 840
aactatgact ccagaaccta ccttatccgt acagtgtccc aacttaccag agaattctat 900
actaaccaga ttcttgaaa cttcgacggt agcttccgta gttctgccca aggtatcgaa 960
ggctccatca ggagcccaca cttgatggac atcttgaaca gcataactat ctacaccgat 1020
gctcacagag gagagatta cttggtctgga caccagatca tggcctctcc agttggatc 1080
agcgggcccg agtttacctt tctctctctat ggaactatgg gaaacgcgcg tccacaacaa 1140
cgatcgttg ctcaactagtg tcagggtgtc tacagaacct tgcctctcac ttgttacaga 1200
agacacctca atatcggtat caacaaccag caactttccg ttcttgacgg aacagagttc 1260
gcctatggaa cctcttctaa cttgccatcc gctgtttaca gaaagagcgg aaccgttgat 1320
tccttggacg aaatcccaac acagaaacac aatgtgccac caggcgaagg attctccac 1380
aggttgagcc acgtgtccat gttccgttcc ggattcagca acagttccgt gagcatcatt 1440

```


<210> 15
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 15
gcttgcaagc ttagaccata tagccc 26

<210> 16
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 16
cgcatgaaa ccggttacac tccca 25

<210> 17
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 17
cttgggcaga accacggaag ctacc 25

<210> 18
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 18
gatgtttgta tggatcctca gccca 25

<210> 19
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

12

<400> 19
gccgaacaat gggtgtaaca aaagg

25